UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
For the quarterly period ended
For the transition period from ___________ to ___________
Commission File Number
CEN BIOTECH, INC.
(Exact name of registrant as specified in its charter)
| | - |
| (State or other jurisdiction of | (I.R.S. Employer |
| | |
| (Address of principal executive offices) | (Zip code) |
(
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| | Smaller reporting company |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes
As of August 12, 2021, there were
TABLE OF CONTENTS
| PART I |
||
| ITEM 1 |
FINANCIAL STATEMENTS |
3 |
| ITEM 2 |
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
25 |
| ITEM 3 |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
35 |
| ITEM 4 |
CONTROLS AND PROCEDURES |
35 |
| PART II |
||
| ITEM 1 |
LEGAL PROCEEDINGS |
36 |
| ITEM 1A |
RISK FACTORS |
36 |
| ITEM 2 |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
36 |
| ITEM 3 |
DEFAULTS UPON SENIOR SECURITIES |
37 |
| ITEM 4 |
MINE SAFETY DISCLOSURE |
37 |
| ITEM 5 |
OTHER INFORMATION |
37 |
| ITEM 6 |
EXHIBITS |
38 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report of CEN Biotech, Inc. (the “Company”) includes “forward-looking statements” that represent our beliefs, projections and predictions about future events. There are statements in this quarterly report that are not historical facts. All statements other than statements of historical fact are “forward-looking statements,” including any projections of earnings, revenue or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning proposed new projects or other developments, any statements regarding future economic conditions or performance, any statements of management’s beliefs, goals, strategies, intentions and objectives, and any statements of assumptions underlying any of the foregoing. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “will,” or any similar expressions, as well as statements in the future tense. These statements are necessarily subjective and involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any future results, performance or achievements described in or implied by such statements.
Forward-looking statements are based on information available at the time those statements are made and management’s belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Although we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance, and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used for the purposes of the forward-looking statements made in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the development of our lines of business and any products that we may manufacture or sell and our ability to raise additional funding sufficient to implement our strategy, as well as assumptions regarding Canadian and U.S. laws regarding the consumer or retail sale of hemp products and accessories and the manufacture and distribution of such products and accessories, including zoning and banking regulations. We also assume that we will be able to raise additional capital to fund our operations while we develop a line of business to generate net revenues. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this quarterly report will in fact transpire. These forward-looking statements are not guarantees of future performance. You are cautioned to not place undue reliance on these forward-looking statements. Except as required by applicable laws, we do not undertake any obligation to update or revise any forward-looking statements.
PART I
| ITEM 1. |
FINANCIAL STATEMENTS |
Contents
Page
| Unaudited condensed consolidated balance sheets |
4 |
| Unaudited condensed consolidated statements of operations |
5 |
| Unaudited condensed consolidated statements of shareholders’ deficit |
6 |
| Unaudited condensed consolidated statements of cash flows |
7 |
| Notes to the unaudited condensed consolidated financial statements |
8 |
CEN BIOTECH, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(Unaudited)
| June 30, 2021 | December 31, 2020 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Prepaid expenses and other assets | ||||||||
| Loan receivable from Emergence Global Enterprises Inc. - related party | ||||||||
| Total current assets | ||||||||
| Other assets | ||||||||
| Other receivable | ||||||||
| Note receivable - CEN Biotech Ukraine LLC - related party | ||||||||
| Advances to CEN Biotech Ukraine LLC - related party | ||||||||
| Intangible assets, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accounts payable – related parties | ||||||||
| Loans payable | ||||||||
| Loans payable – related parties | ||||||||
| Convertible notes payable | ||||||||
| Convertible notes payable- related parties | ||||||||
| Accrued interest | ||||||||
| Accrued interest – related parties | ||||||||
| Lease liabilities | ||||||||
| Accrued expenses | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, less current portion | ||||||||
| Patent acquisition liability | ||||||||
| Convertible notes, less current portion | ||||||||
| Total liabilities | ||||||||
| Shareholders’ deficit | ||||||||
| Common stock; authorized shares; and issued and outstanding as of June 30, 2021 and December 31, 2020, respectively. par value. | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total shareholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and shareholders’ deficit | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
| CEN BIOTECH, INC. AND SUBSIDIARY |
| Condensed Consolidated Statements of Operations |
| (Unaudited) |
| For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Consulting fees | $ | $ | $ | $ | ||||||||||||
| Consulting fees – related parties | ||||||||||||||||
| Stock based compensation | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense – related parties | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest income | ||||||||||||||||
| Change in fair value of patent acquisition liability | ||||||||||||||||
| Foreign exchange (loss) gain | ( | ) | ( | ) | ( | ) | ||||||||||
| Other income (expense), net | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares outstanding | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
| CEN BIOTECH, INC. AND SUBSIDIARY |
|||||
| Condensed Consolidated Statements of Shareholders’ Deficit |
|||||
| (Unaudited) |
| For the three months ended June 30: | Common | Additional | Total | |||||||||||||||||
| Common | Shares | Paid-in | Accumulated | Shareholders’ | ||||||||||||||||
| Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||
| Balances, April 1, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | ||||||||||||||||||||
| Issuance of common stock – interest shares | ||||||||||||||||||||
| Issuance of common stock - consulting | ||||||||||||||||||||
| Issuance of common stock - settlement of accrued liability | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balances, June 30, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Balances, April 1, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | ||||||||||||||||||||
| Beneficial conversion feature on convertible notes issued | - | |||||||||||||||||||
| Issuance of common stock – upon conversion of convertible notes | ||||||||||||||||||||
| Issuance of common stock – upon conversion of convertible notes – related parties | ||||||||||||||||||||
| Issuance of common stock – interest shares | ||||||||||||||||||||
| Issuance of common stock – consulting | ||||||||||||||||||||
| Issuance of common stock – settlement of accrued interest | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balances, June 30, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| For the six months ended June 30: | Common | Additional | Total | |||||||||||||||||
| Common | Shares | Paid-in | Accumulated | Shareholders’ | ||||||||||||||||
| Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||
| Balances, January 1, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | ||||||||||||||||||||
| Issuance of common stock – interest shares | ||||||||||||||||||||
| Issuance of common stock - consulting | ||||||||||||||||||||
| Issuance of common stock - settlement of accrued liability | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balances, June 30, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Balances, January 1, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | ||||||||||||||||||||
| Beneficial conversion feature on convertible notes issued | - | |||||||||||||||||||
| Issuance of common stock – upon conversion of convertible notes | ||||||||||||||||||||
| Issuance of common stock – upon conversion of convertible notes – related parties | ||||||||||||||||||||
| Issuance of common stock – interest shares | ||||||||||||||||||||
| Issuance of common stock – consulting | ||||||||||||||||||||
| Issuance of common stock – settlement of accrued interest | ||||||||||||||||||||
| Issuance of common stock – settlement of accrued liability | ||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||
| Balances, June 30, 2021 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| See accompanying notes to condensed consolidated financial statements. |
| CEN BIOTECH, INC. AND SUBSIDIARY |
| Condensed Consolidated Statements of Cash Flows |
| (Unaudited) |
| For the six months ended June 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Depreciation | ||||||||
| Amortization | ||||||||
| Amortization of debt discount | ||||||||
| Lease expense | ||||||||
| Stock-based compensation – employees | ||||||||
| Stock-based compensation – non-employees | ||||||||
| Shares issued for interest | ||||||||
| Change in fair value of patent acquisition liability | ( | ) | ||||||
| Foreign exchange loss (gain) | ( | ) | ||||||
| Changes in operating assets and liabilities which provided (used) cash | ||||||||
| Prepaid expenses and other assets | ||||||||
| Other receivable | ||||||||
| Accounts payable | ||||||||
| Accounts payable – related parties | ||||||||
| Accrued interest – related and non-related parties | ||||||||
| Accrued expenses | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows used in investing activities | ||||||||
| Advances to CEN Biotech Ukraine LLC | ( | ) | ||||||
| Cash flows provided by financing activities | ||||||||
| Repayment of loans payable - related parties | ( | ) | ||||||
| Issuance of convertible notes | ||||||||
| Issuance of convertible notes – related parties | ||||||||
| Net cash provided by financing activities | ||||||||
| Net increase in cash and cash equivalents | ||||||||
| Cash and cash equivalents, beginning of period | ||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental cash flows disclosures | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Non-cash transactions - investing and financing activities | ||||||||
| Issuance of common stock - settlement of interest | $ | $ | ||||||
| Issuance of common stock - settlement of accrued liability | $ | $ | ||||||
| Issuance of common stock – upon conversion of convertible notes | $ | $ | ||||||
| Issuance of common stock – upon conversion of convertible notes - related parties | $ | $ | ||||||
| Beneficial conversion feature in connection with issuance of convertible notes | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
CEN BIOTECH, INC. AND SUBSIDIARY
Notes to the Condensed Consolidated Financial Statements (Unaudited)
(All amounts are in US dollars unless otherwise stated.)
NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the condensed consolidated financial statements of the Company for the year ended December 31, 2020 and notes thereto.
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
Loss per Share
Net loss per common share is computed pursuant to ASC 260-10-45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three and six-months ended June 30, 2021 and 2020, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.
Recent Developments
In April of 2021, the Company’s common stock began to be quoted on the OTC Link alternative trading system (operated by OTC Markets Group Inc.) under the trading symbol “CENBF” on the OTC Pink tier. There is no assurance that an active trading market for our shares will develop or will be sustained if developed.
On April 19, 2021, the Board appointed Mr. Bahige (Bill) Chaaban to serve as Chief Executive Officer of the Company effective April 19, 2021. On the same date, the Board appointed Mr. Joseph Byrne to serve as President and a member of the Board of the Company effective April 19, 2021. On the same, date, the Board appointed Mr. Rick Purdy to serve as a member of the Board of the Company effective April 19, 2021. On the same date, the Board appointed Mr. Jeffrey Thomas to serve as a member of the Board of the Company effective April 19, 2021.
On April 20, 2021, the Company entered into a Share Exchange Agreement (the “Agreement”) with Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), each of the shareholders of CCM as set forth on the signature pages of the Agreement (the “CCM Shareholders”) and Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”, each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties”). Pursuant to the Agreement, the Company agreed to acquire from the CCM Shareholders, all of the common shares of CCM, which is
At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one and to appoint and named the Shareholder Representative as a member of the Board of the Company. Additionally, at Closing, the Company appointed and named the Shareholder Representative as the Company’s Chief Technology Officer.
At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $
Recently Adopted Accounting Pronouncements
No pronouncements were adopted by the Company during the six-month period ended June 30, 2021.
Recent Accounting Pronouncements Not Yet Adopted
In August 2020, the Financial Accounting Standards Board (“FASB”) issued an accounting pronouncement (ASU 2020-06) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity's own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity's own equity. As a smaller reporting company, as defined by the SEC, this pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2023. The Company is currently evaluating the impact of this ASU on the consolidated financial statements.
NOTE 2 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS
The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $
The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.
NOTE 3 – ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL
At December 31, 2020, the Company had an outstanding loan receivable of $
At June 30, 2021 and December 31, 2020, the Company had advances of $
Bahige (Bill) Chaaban, our Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own
NOTE 4 – INTANGIBLE ASSETS
On September 12, 2016, the Company executed an agreement dated August 31, 2016, to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian Corporation, and Stevan (Steve) Pokrajac (the “Sellers”).
Material consideration given by Company was: (a) Shares of CEN common stock equal to $
The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 between the Company and the Sellers, CEN has reaffirmed the rights to use the patented technology.
In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not yet been formed, in connection with the development of the acquired technology with compensation equal to $
In March 2018, the Tesla agreement was amended to replace the $
The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no fair value.
The intangible asset consists of the following at:
| June 30, 2021 | December 31, 2020 | |||||||
| Lighting patent | $ | $ | ||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| Net | $ | $ | ||||||
As of June 30, 2021 and December 31, 2020, there is
NOTE 5 – LOANS PAYABLE
Loans payable consist of the following at:
| June 30, 2021 | December 31, 2020 | |||||||
| Loan payable to Global Holdings International, LLC, which bears interest at per annum after defaulting on the maturity date of . This note was previously secured by equipment that the Company disposed of on August 1, 2020. | $ | $ | ||||||
| Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD . The mortgage bears interest at per annum, is unsecured, and matured on . | ||||||||
| Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of common shares per 30-day period. This is an unsecured loan which matures on . | ||||||||
| Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of common shares per 30-day period. This is an unsecured loan which matures on . | ||||||||
| Loans payable in default to multiple private investors bearing an interest at rates of up to per annum, maturing at various dates between and . | ||||||||
| Total loans payable (all current) | $ | $ | ||||||
During each of the three-month periods ended June 30, 2021 and 2020,
During each of the six-month periods ended June 30, 2021 and 2020,
During the three-month period ended June 30, 2021, certain private investors amended their convertible notes payable totaling $
NOTE 6 – LOANS PAYABLE- RELATED PARTY
Loans payable - related party consists of the following at:
| June 30, 2021 | December 31, 2020 | |||||||
| Loans payable in default to the spouse of Bill Chaaban, CEO of CEN, for the original amounts of CAD and USD $, bear interest at per annum. These are unsecured loans that matured on . | $ | $ | ||||||
| Loans payable in default to a former director of Creative, former parent company, bear interest at per annum. This are unsecured loans that matured on . | ||||||||
| Loan payable in default to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the CEO of CEN, bearing interest at per annum. This is an unsecured loan that matured on . R&D Labs Canada is a company owned by Bill Chaaban’s spouse. | ||||||||
| Loan payable to the spouse of Joseph Byrne, a shareholder and former CEO, and current President and member of the board of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of common shares per 30-day period. This is an unsecured loan that matures on . | ||||||||
| Loan payable to Alex Tarrabain, CFO and a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of common shares per 30-day period. This is an unsecured loan that matures on . | ||||||||
| Loan payable to Joseph Byrne, a shareholder and former CEO, and current President and member of the board of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of common shares per 30-day period. This loan was repaid in June 2021. | ||||||||
| Total loans payable - related party (all current) | $ | $ | ||||||
Attributable related party accrued interest was $
During both three-month periods ended June 30, 2021 and 2020,
During both six-month periods ended June 30, 2021 and 2020,
NOTE 7 – CONVERTIBLE NOTES
Convertible notes payable consists of the following at:
| June 30, 2021 | December 31, 2020 | |||||||
| Convertible note payable, due on demand, for the original amount of CAD , bearing interest at per annum with conversion rights for common shares. | $ | $ | ||||||
| Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at per annum with conversion rights for common shares, maturing at various dates between and . | ||||||||
| Convertible notes payable with beneficial conversion features at original issuance to multiple private investors, bearing interest at per annum with conversion rights for common shares, maturing at various dates in . | ||||||||
| Total convertible notes payable | ||||||||
| Less unamortized debt discount | ||||||||
| Total convertible notes payable, net of unamortized debt discount | ||||||||
| Less current portion | ||||||||
| Convertible notes payable, less current portion | $ | $ | ||||||
The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during both the three and six-month periods ended June 30, 2021 to be $
These notes may be converted at the option of the note holder upon written notice by the note holder. These notes are convertible into a total of
During the three-month period ended June 30, 2021, certain private investors elected to exercise their convertible notes payable totaling $
During the three-month period ended June 30, 2021, certain private investors elected to convert $
As of August 12, 2021, we are currently in default of $
NOTE 8 – CONVERTIBLE NOTES PAYABLE - RELATED PARTIES
Convertible notes payable - related parties consists of the following at:
| June 30, 2020 | December 31, 2020 | |||||||
| Convertible note in default due to the spouse of Bill Chaaban, CEO of CEN, which bears an interest at per annum. This note is convertible to common shares and matured on . | $ | $ | ||||||
| Convertible notes in default due to Harold Aubrey de Lavenu, a Vice President and Director of CEN, bearing interest at per annum. These notes are convertible to common shares and matured on . | ||||||||
| Convertible notes in default due to Joseph Byrne, former CEO, and current President and member of the board of CEN, bearing interest at per annum. This note is convertible to common shares and matured on . | ||||||||
| Convertible notes with beneficial conversion features due to the parents of Jeffery Thomas, a Director of CEN, bearing interest at per annum. These notes are convertible to common shares with a maturity date of . | ||||||||
| Convertible note in default due to Alex Tarrabain, CFO and a Director of CEN, bearing interest at per annum. On April 10, 2021, this note was converted to common shares. | ||||||||
| Convertible note due to Darren Ferris, brother of Ameen Ferris, a Vice President and a Director of CEN, bearing interest at per annum. On April 26, 2021, this note was converted to common shares. | ||||||||
| Total convertible notes payable – related parties | ||||||||
| Less unamortized debt discount | ||||||||
| Total convertible notes payable - related parties (all current) | $ | $ | ||||||
Attributable related party accrued interest was $
The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance.
The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during both the three and six-month periods ended June 30, 2021 to be $
These notes may be converted at the option of the note holder upon written notice by the note holder. These notes are convertible into a total of
During the three-month period ended June 30, 2021, a convertible note due to Joseph Byrne in the amount of $
As of August 12, 2021, we are currently in default of $
NOTE 9 – INCOME TAXES
A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three and six-months ended June 30:
| 2021 | 2020 | |||||||
| Income tax benefit at Canadian statutory rate | % | % | ||||||
| Valuation allowance | ( | %) | ( | %) | ||||
| Effective income tax rate | % | % | ||||||
As of June 30, 2021, the Company has net operating loss carry forwards of approximately $
| June 30, 2021 | December 31, 2020 | |||||||
| Deferred tax asset - net operating losses | $ | $ | ||||||
| Deferred tax asset valuation allowance | ( | ) | ( | ) | ||||
| Net deferred tax asset | $ | $ | ||||||
The valuation allowance increased $
Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of June 30, 2021, there are no uncertain income tax positions taken or expected to be taken that would require recognition of a liability or disclosure in the condensed consolidated financial statements. The Company is subject to routing audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. Generally, the Company is no longer subject to income tax examinations for years prior to 2017.
NOTE 10 – SHAREHOLDERS’ DEFICIT / STOCK ACTIVITY
The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have
As of June 30, 2021,
NOTE 11 – RELATED PARTY TRANSACTIONS
The Company has received loans from several related parties, as described above in Notes 6 and 8.
A loan totaling $
There are advances of $
On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at
During the three-months ended June 30, 2021 and 2020, the Company incurred payroll and consulting expenses of $
During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $
Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased 20 North Rear Road, a 10.4 acre site of land in Canada which included two buildings and a security vault, to the Company under an agreement effective January 2017 for monthly rental payments of CAD
The Company also leased office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. This lease was subsequently assigned to RN Holdings Ltd, a third-party, on May 8, 2019 when RN holdings purchased the building. Under the lease agreement effective October 1, 2017, monthly rents of CAD
Effective with the August 1, 2020 lease termination and abandonments, all property, plant, and improvements, which were located at these properties were abandoned.
Maturities of the operating lease liability for the 12 months subsequent to June 30, 2021 was as follows:
| Amount | ||||
| 2022 | $ | |||
| 2023 | ||||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| Thereafter | ||||
| Total lease payments | $ | |||
| Less imputed interest | ||||
| Present value of lease liability | $ | |||
NOTE 12 – STOCK BASED COMPENSATION
Adoption of Equity Compensation Plan
On November 29, 2017, the Board adopted the 2017 Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved
On April 2, 2021, the Board of Directors of the Company adopted the 2021 Equity Compensation Plan (the “2021 Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants of the Company and reserved an additional
Equity Compensation Grants
On November 30, 2017, the Company granted a one-time equity award (“Equity Award”) of restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement to certain executives and directors of the company. Donald Strilchuck, Director, received
On October 1, 2019, the Company entered into an agreement with a communications and branding firm for the payment of its services under which the Company issued
On April 17, 2020, the Company entered into agreements with three individuals for the payment of business consulting services under which the Company issued
On August 27, 2020 and September 25, 2020, the Company entered into agreements with two individuals for the payment of business consulting services under which the Company issued an aggregate of
On April 2, 2021, a consulting agreement with CONFIEN SAS for business coaching was entered into for a period of 12 months. As payment for these services,
Employment Agreements
On November 30, 2017, employment agreements were entered into with four key members of management:
| ● | Under the Employment Agreement with Bahige (Bill) Chaaban, then President of the Company, Mr. Chaaban agreed to receive compensation in the form of a base annual salary of $ |
| ● | Under the Employment Agreement with Joseph Byrne, former Chief Executive Officer of the Company, Mr. Byrne agreed to receive compensation in the form of a base annual salary of $ |
| ● | Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and then Chief Financial Officer of the Company, Mr. Boswell agreed to receive compensation in the form of a base annual salary of $ |
| ● | Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne agreed to receive compensation in the form of a base annual salary of and a grant of |
On May 16, 2019, the Board appointed Alex Tarrabain, one of the members of the Company’s Board to serve as the Company’s Chief Financial Officer and as one of the Vice Presidents of the Company effective May 21, 2019 (the “Effective Date”). Richard Boswell, who served as the Company’s Chief Financial Officer since July 2017, resigned from his position as the Company’s Chief Financial Officer as of the Effective Date, continues to serve in his position as the Company’s Senior Executive Vice President going forward focusing on the Company’s strategic activities and will also continue to serve as a member of the Company’s Board.
In conjunction with the above, on May 16, 2019, an employment agreement was entered into with Mr. Tarrabain:
| ● | Under the Employment Agreement with Alex Tarrabain, Chief Financial Officer and as one of the Vice Presidents of the Company, Mr. Tarrabain agreed to receive compensation in the form of a base annual salary of $ |
On April 2, 2021, the Board of Directors appointed Ameen Ferris and Harold Aubrey De Lavenu to serve as Vice Presidents of the Company. Under the associated Executive Employment Agreements, they will each receive compensation in the form of a base annual salary of $
On April 2, 2021, the Company entered into an RSA (the “Boswell RSA”) with Richard Boswell. Pursuant to the Boswell RSA, the Company granted Mr. Boswell
On April 2, 2021, the Company entered into an RSA (the “Chaaban RSA”) with Bahige Chaaban. Pursuant to the Chaaban RSA, the Company granted Mr. Chaaban
On April 2, 2021, the Company entered into an RSA (the “Payne RSA”) with Brian Payne. Pursuant to the Payne RSA, the Company granted Mr. Payne
On April 2, 2021, the Company entered into an RSA (the “Saadikh RSA”) with Usamakh Saadikh. Pursuant to the Saadikh RSA, the Company granted Mr. Saadikh
On April 2, 2021, the Company entered into an RSA (the “Strilchuck RSA”) with Donald Strilchuck. Pursuant to the Strilchuck RSA, the Company granted Mr. Strilchuck
On April 2, 2021 and June 25, 2021, the Company entered into an RSA (the “Tarrabain RSA”) with Alex Tarrabain. Pursuant to the Tarrabain RSA, the Company granted Mr. Tarrabain
Restricted Stock Awards
Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants.
The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $
With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally years from the grant-date. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.
During the three-month periods ended June 30, 2021 and 2020,
Compensation expense recognized in connection with the restricted stock awards was $
Non-vested restricted stock award activity for the six-months ended June 30, 2021 and 2020 are as follows:
| Number of Shares | Weighted- Average Grant Date Fair Value per Share | Weighted- Average Remaining Contractual Term (Years) | ||||||||||
| Non-vested at January 1, 2020 | $ | |||||||||||
| Granted | - | |||||||||||
| Vested | ( | ) | - | |||||||||
| Forfeited | - | |||||||||||
| Non-vested at June 30, 2020 | $ | |||||||||||
| Non-vested at January 1, 2021 | $ | |||||||||||
| Granted | - | |||||||||||
| Vested | ( | ) | - | |||||||||
| Forfeited | - | |||||||||||
| Non-vested at June 30, 2021 | $ | |||||||||||
The fair value of the restricted stock grants was based on the valuation of a third-party specialist prior to April 5, 2021. Beginning April 5, 2021, the fair value of the restricted stock grants is based upon the daily closing price per the OTC Link. As of June 30, 2021, unrecognized compensation expense totaled $
NOTE 13 – NET LOSS PER SHARE
During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of June 30, 2021 and 2020. Common stock equivalents that were excluded for the three and six-month periods ended June 30, 2021 and 2020 are as follows:
| Three-months Ended June 30, | Six-months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Convertible debt | ||||||||||||||||
NOTE 14 – CONTINGENCY
In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.
NOTE 15 – FAIR VALUE DISCLOSURES
Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.
The fair value of the Company’s financial instruments are as follows at:
| Fair Value Measured at Reporting Date Using | ||||||||||||||||||||
| Carrying Amount | Level 1 | Level 2 | Level 3 | Fair Value | ||||||||||||||||
| At June 30, 2021: | ||||||||||||||||||||
| Cash and cash equivalents | $ | $ | $ | $ | $ | |||||||||||||||
| Other receivables | $ | $ | $ | $ | $ | |||||||||||||||
| Note receivable – CEN Biotech Ukraine, LLC – related party | $ | $ | $ | $ | $ | |||||||||||||||
| Advances to CEN Biotech Ukraine, LLC - related party | $ | $ | $ | $ | $ | |||||||||||||||
| Loans payable | $ | $ | $ | $ | $ | |||||||||||||||
| Loans payable – related parties | $ | $ | $ | $ | $ | |||||||||||||||
| Patent acquisition liability | $ | $ | $ | $ | $ | |||||||||||||||
| Convertible notes payable | $ | $ | $ | $ | $ | |||||||||||||||
| Convertible notes payable – related parties | $ | $ | $ | $ | $ | |||||||||||||||
| Carrying Amount | Level 1 | Level 2 | Level 3 | Fair Value | ||||||||||||||||
| At December 31, 2020: | ||||||||||||||||||||
| Cash and cash equivalents | $ | $ | $ | $ | $ | |||||||||||||||
| Other receivables | $ | $ | $ | $ | $ | |||||||||||||||
| Note receivable – CEN Biotech Ukraine, LLC – related party | $ | $ | $ | $ | $ | |||||||||||||||
| Advances to Emergence Global - related party | $ | $ | $ | $ | $ | |||||||||||||||
| Advances to CEN Biotech Ukraine, LLC - related party | $ | $ | $ | $ | $ | |||||||||||||||
| Loans payable | $ | $ | $ | $ | $ | |||||||||||||||
| Loans payable – related parties | $ | $ | $ | $ | $ | |||||||||||||||
| Patent acquisition liability | $ | $ | $ | $ | $ | |||||||||||||||
| Convertible notes payable | $ | $ | $ | $ | $ | |||||||||||||||
| Convertible notes payable – related parties | $ | $ | $ | $ | $ | |||||||||||||||
The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments.
The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.
The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.
It is not practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.
The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3rd party valuation specialist prior to April 5, 2021. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies. Beginning April 5, 2021, the fair value of the patent acquisition liability is based upon the OTC closing price and accordingly was transferred from Level 3 to Level 1 due to the availability of published prices for CEN’s common stock.
NOTE 16 – SUBSEQUENT EVENTS
From July 1, 2021 to August 12, 2021, the Company authorized the issuance of
From July 1, 2021 to August 12, 2021, the Company issued 1 new convertible notes totaling $
On July 13, 2021, the Company entered into an RSA (the “Keane RSA”) with Patrick Keane. Pursuant to the Keane RSA, the Company granted Mr. Keane
On July 13, 2021, the Company entered into an RSA (the “Scott RSA”) with Daniel Scott. Pursuant to the Scott RSA, the Company granted Mr. Scott
On April 20, 2021, the Company entered into a Share Exchange Agreement (the “Agreement”) with Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), each of the shareholders of CCM as set forth on the signature pages of the Agreement (the “CCM Shareholders”) and Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”, each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties”). Pursuant to the Agreement, the Company agreed to acquire from the CCM Shareholders, all of the common shares of CCM, which is
ITEM 2
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the Notes to those financial statements that are included elsewhere in this Quarterly Report on Form 10-Q. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under Special Note Regarding Forward-Looking Statements. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.
Background and Overview
CEN Biotech, Inc. (“we,” “us,” “our” or “CEN” or the “Company”) is a Canadian holding company, incorporated in Canada on August 4, 2013 as a subsidiary of Creative Edge Nutrition, Inc. (“Creative”), a Nevada corporation. Creative separated its planned specialty pharmaceutical business located in Canada by transferring substantially all of the assets and liabilities of the planned specialty pharmaceutical business to CEN and effecting a distribution (the “Spin-Off Distribution”) of CEN common stock to Creative shareholders on February 29, 2016. The Spin-Off Distribution was intended to be tax free for U.S. federal income tax purposes.
Prior to the Spin Off Distribution, the Company initially pursued the cannabis business in Canada and obtained funding to build the initial phase of its comprehensive seed-to-sale facility and applied to obtain a license in Canada to begin operating its state-of-the-art medical marijuana cultivation, processing, and distribution facility in Lakeshore, Ontario. On March 11, 2015, the Company’s application for a license to produce marijuana for medical purposes was formally rejected by Canadian regulatory authority. On February 1, 2016 the Company commenced legal action against the Attorney General of Canada in the Ontario Superior Court of Justice for damages for detrimental reliance, economic loss, and prejudgment and post judgment interest, costs of the proceeding and other relief that the court may seem just. As of August 12, 2021 the action in the Ontario Superior Court of Justice is still ongoing. In the meantime the Company decided to develop and pursue other businesses that are related to Light Emitting Diode (“LED”) lighting and hemp-based industrial, medical and food products that have a tetrahydrocannabinol (“THC”) that is below 0.3%.
We are currently focused on the manufacturing, production and development of LED lighting technology and hemp-based products. The Company intends to continue to explore the usage of hemp, which it now intends to cultivate for usage in industrial, medical and food products. We also plan to expand our business to include Cannabis, Psychedelic Mushrooms, and Digital Communities. Our mission is to strive to be an agriculture based mindful provider of Phyto medical solutions developed to help improve "your" state of health and well-being.
Our principal office is located at 300-3295 Quality Way, Windsor, Ontario, Canada, N8T 3R9 and our phone number is (519) 419-4958. Our corporate website is located at http://www.cenbiotechinc.com. The information contained on or connected to our website is not part of this report and is not incorporated herein.
We have not yet generated any revenues, and at present we are not able to estimate if or when we will be able to generate any revenues. Our consolidated financial statements have been prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, management, as well as our auditors, have determined there is substantial doubt about our ability to continue as a going concern.
At June 30, 2021 and December 31, 2020, the Company had advances of $1,299,328 and $1,179,328, respectively, to CEN Ukraine which is a related party. The advances were for the purpose of funding the operations of CEN Ukraine. These advances were substantially used as follows:
| ● |
Approximately $420,000 to operate its office in Kiev; |
| ● |
Approximately $445,328 to employ several workers; |
| ● |
Approximately $350,000 for performing multiple test crops; |
| ● |
Approximately $75,000 for oil processing activities; and |
| ● |
Approximately $9,000 for payment of rent. |
Plan of Operations
Plan of Operations of CEN Biotech Inc.
Our monthly “burn rate,” the amount of expenses we expect to incur on a monthly basis, is approximately $100,000 for a total of $1,200,000 for the maximum of 12 months. We have relied and will continue to rely on capital raised from third parties to fund our operating expenses during the following 12 months.
In order to complete our plan of operations, we estimate that $8,700,000 in funds will be required. The source of such funds is anticipated to be from capital raised from third parties. If we fail to generate $8,700,000 of funds from capital raised, we may not be able to fully carry out our plan of operations.
Generally, the funds are planned to be invested as follows: $2.3 million in hemp activities, $2.5 million in LED lighting manufacturing, $200,000 to obtain quotation on OTCQB, $2.5 million to complete acquisitions in the phyto medical space including cannabis and psychedelic mushrooms and $1.2 million in general operating costs. There can be no assurance that the Company will be able to raise the foregoing funds or proceed as planned.
We hope to reach the following milestones in the next 12 months:
| ● |
February 2022 – The Company intends to close a minimum of two acquisitions in the phyto medical space and we estimate the cost of this to be $1,250,000. |
| ● |
June 2022 - The Company intends to close an additional two acquisitions in the phyto medical space and we estimate the cost of this to be $1,250,000. |
| ● |
October 2021 – The Company intends to obtain quotation on OTCQB and we estimate the costs of this to be $200,000. |
| ● |
October 2021 – The Company intends to close on its contract with CEN Ukraine and we estimate the costs of this to be $300,000. |
| ● |
October 2021 to December 2024 – The Company intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products through CEN Ukraine as follows: |
| ● |
Secure lease of processing facility expected to take place in November, 2021 and we estimate the costs of this to be $400,000 annually. |
| ● |
Purchase of seeds for production crop expected to take place in November, 2021 and we estimate the costs of this to be $100,000 annually. |
| ● |
Hire farming and production staff expected to take place in March, 2022 and we estimate the costs of this to be $600,000 annually. |
| ● |
Rent farming equipment, purchase fuel, irrigation, and nutrients expected to take place in April, 2022 and we estimate the costs of this to be $600,000 annually. |
| ● |
Market, package and ship product expected to take place in July, 2022 and we estimate the costs of this to be $300,000 annually. |
| ● |
September 2021 – The Company intends to close on its contract with Tesla Digital, Inc. regarding the LED lighting patent and we estimate the costs of this to be $300,000. |
| ● |
October 2021 to December 2024 – The Company intends to explore using the LED lighting patent across manufacturing operations and licensing opportunities across multiple industries such as the horticultural industry, as well as the automotive, industrial and commercial lighting industries as follows: |
| ● |
Lease production facility expected to take place in December 2021 and we estimate the costs of this to be $400,000 annually. |
| ● |
Lease equipment expected to take place in December, 2021 and we estimate the costs of this to be $400,000 annually. |
| ● |
Hire staff expected to take place in December, 2021 and we estimate the costs of this to be $600,000 annually. |
| ● |
Initial raw materials expected to take place in December, 2021 and we estimate the costs of this to be $500,000 one time. |
| ● |
Marketing and delivery expected to take place in April, 2022 and we estimate the costs of this to be $300,000 annually. |
Achievement of the milestones will depend highly on our funds and the availability of those funds. There can be no assurance that we will be able to successfully complete such milestones.
Plan of Operations of Clear Com Media, Inc.
The current burn rate for CCM inclusive of all wages and operating costs are approximately $120,000 CDN per month or $1,440,000 CDN per year (Approx. $1,152,000 USD) per year. We anticipate an increase of 40% in this burn rate for wages for senior software developers and network engineers as well as a modest marketing spend for the launch of one of CCM’s new products and services anticipated for commercialization in Q4 of 2021.
The following highlights the major goals and activities planned for the next twelve months:
| ● |
Expansion of CCM’s enterprise hosting infrastructure for CCM’s client services and CCM products to address the ongoing growth needs of the business. |
| ● |
Completion of the Chatter product and service that is expected to launch in Q4 of 2021. This product in currently in the final stages of development and is expected to be completed in the end of Q3 with testing and marketing to commence on the final quarter of 2021. |
| ● |
Continued development on the BIO Blockchain permission platform that will continue for the next twelve months and beyond. The ongoing development cost of this project is estimated to be $25,000 per month until completed. |
| ● |
Continued development of internal efficiency processes and automated systems for tasks such as workflow, billing, subscriptions, security and internal cloud computing. |
| ● |
Development, deployment and management of a modest online marketing campaign for the launch of the Chatter service which is expected to commence in Q4 of 2021 and continue on a more aggressive path after month 12 and onward. |
| ● |
Continued development of the digital community project (Project Juno) that is expected to continue well into 2022 with an estimated completion date of Q4 2022. This project will require the hiring of additional skilled developers and software engineers to focus on new R&D initiatives for a future consumer and business focused product and service. The development cost of this project is estimated to be $600,000 for a minimum viable product and ongoing expansion costs of $40,000 per month in perpetuity. |
| ● |
Continued support and a modest expansion of the core services offered by to our key business partners and direct customers. These services include but are not limited to software and web development. SEO, social media marketing, mobile app development and online digital marketing. |
Continue to investigate potential strategic acquisitions to add to the organization that can assist in accelerating and amplifying the goals of the organization.
Recent Developments
The outbreak of a novel coronavirus (COVID-19), which the World Health Organization declared in March 2020 to be a pandemic, continues to spread throughout the United States of America and the globe. Many State Governors issued temporary Executive Orders that, among other stipulations, effectively prohibit in-person work activities for most industries and businesses, having the effect of suspending or severely curtailing operations. The extent of the ultimate impact of the pandemic on the Company's operational and financial performance will depend on various developments, including the duration and spread of the outbreak, and its impact on potential customers, employees, and vendors, all of which cannot be reasonably predicted at this time. While management reasonably expects the COVID-19 outbreak to negatively impact the Company's financial condition, operating results, and timing and amounts of cash flows, the related financial consequences and duration are highly uncertain.
On April 2, 2021, the Board of Directors of the Company adopted the 2021 Equity Compensation Plan (the “2021 Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants of the Company and reserved 20,000,000 shares of the Company’s common stock for issuance under the 2021 Plan.
On April 2, 2021, the Board of Directors appointed Ameen Ferris and Harold Aubrey De Lavenu to serve as Vice Presidents of the Company. Under the associated Executive Employment Agreements, they will each receive compensation in the form of a base annual salary of $31,200. In addition, Ameen Ferris was granted 1,000,000 and Harold Aubrey De Lavenu was granted 1,041,250 restricted shares of the Company’s common stock subject to applicable securities laws and regulations. Such shares vested immediately. The expense related to the restricted stock awarded to employees for services previously rendered was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Boswell RSA”) with Richard Boswell. Pursuant to the Boswell RSA, the Company granted Mr. Boswell 2,185,679 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. On April 2, 2021, the Company entered into an RSA (the “Chaaban RSA”) with Bahige Chaaban. Pursuant to the Chaaban RSA, the Company granted Mr. Chaaban 3,106,122 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. On April 2, 2021, the Company entered into an RSA (the “Payne RSA”) with Brian Payne. Pursuant to the Payne RSA, the Company granted Mr. Payne 1,435,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. On April 2, 2021, the Company entered into an RSA (the “Saadikh RSA”) with Usamakh Saadikh. Pursuant to the Saadikh RSA, the Company granted Mr. Saadikh 1,000,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. On April 2, 2021, the Company entered into an RSA (the “Strilchuck RSA”) with Donald Strilchuck. Pursuant to the Strilchuck RSA, the Company granted Mr. Strilchuck 341,250 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. On April 2, 2021, the Company entered into an RSA (the “Tarrabain RSA”) with Alex Tarrabain. Pursuant to the Tarrabain RSA, the Company granted Mr. Tarrabain 300,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued pursuant to the RSAs are restricted shares and are subject to applicable securities laws and regulations as set forth in the RSAs. The shares were issued for services previously rendered was recognized on the applicable grant dates.
On April 2, 2021, a consulting agreement with CONFIEN SAS for business coaching was entered into for a period of 12 months. As payment for these services, 650,000 restricted shares subject to applicable securities laws and regulations of the Company’s common stock were granted. Such shares vested immediately. The expense related to the restricted stock awarded to non-employees for services previously rendered was recognized on the grant date.
In April of 2021, the Company’s common stock began to be quoted on the OTC Link alternative trading system (operated by OTC Markets Group Inc.) under the trading symbol “CENBF” on the OTC Pink tier. There is no assurance that an active trading market for our shares will develop or will be sustained if developed.
On April 19, 2021, the Board appointed Mr. Bahige (Bill) Chaaban to serve as Chief Executive Officer of the Company effective April 19, 2021. On the same date, the Board appointed Mr. Joseph Byrne to serve as President and a member of the Board of the Company effective April 19, 2021. On the same, date, the Board appointed Mr. Rick Purdy to serve as a member of the Board of the Company effective April 19, 2021. On the same, date, the Board appointed Mr. Jeffrey Thomas to serve as a member of the Board of the Company effective April 19, 2021.
On April 20, 2021, the Company entered into a Share Exchange Agreement (the “Agreement”) with Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), each of the shareholders of CCM as set forth on the signature pages of the Agreement (the “CCM Shareholders”) and Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”, each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties”). Pursuant to the Agreement, the Company agreed to acquire from the CCM Shareholders, all of the common shares of CCM, which is 10,000 shares of CCM common shares (the “CCM Stock”) held by the CCM Shareholders in exchange (the “Exchange”) for the issuance by the Company to the CCM Shareholders of 4,000,000 restricted shares of the Company’s common stock, no par value per share (the “Company Common Stock”). The Agreement closed on July 9, 2021 (the “Closing”). At Closing, the CCM Shareholders delivered the CCM Stock to the Company and the Company delivered the Company Common Stock to the CCM Shareholders, and CCM became a wholly owned subsidiary of the Company. At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one and to appoint and named the Shareholder Representative as a member of the Board of the Company. Additionally, at Closing, the Company appointed and named the Shareholder Representative as the Company’s Chief Technology Officer. At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux a base salary of $31,200. Clear Com Media Inc. is a Windsor, Ontario based data management, digital marketing and Ecommerce company founded on the premise that we are not satisfied until our customers are. Clear Com is entirely committed to delivering a positive customer experience while continuing to grow and gaining the trust of the online community. Clear Com seeks to let nothing stop it from delivering a positive personal experience by focusing on data driven decision making. By exemplifying professionalism and expertise in technology Clear Com seeks to ensure customer satisfaction every step of the way.
At December 31, 2020, the Company had an outstanding loan agreement with Emergence Global Enterprises Inc. (“Emergence Global”), and advanced funds of $17,901. At the time the loan was made, Joseph Byrne, the CEO of Emergence Global was not an officer or director of the company. He was at that time a 5% shareholder and former CEO of the Company. He was then appointed as the President and a director of the Company on April 19, 2021. Additionally, our CEO, Bill Chaaban was appointed as the President of Emergence Global on April 12, 2021. In light of Section 402 of the Sarbanes-Oxley Act of 2002, as of May 6, 2021, the loan to Emergence Global has been repaid in full, through the issuance to the Company of shares of Emergence Global common stock, and is no longer outstanding. The Company and Emergence Global entered into that certain Loan Repayment Agreement dated as of May 6, 2021, pursuant to which Emergence Global agreed to repay to the Company $17,901, representing the total amount then outstanding under the loan agreement, by issuing 21,830 shares of Emergence Global common stock, $0.82 par value per share. Such shares were issued to the Company on May 6, 2021.
On June 25, 2021, the Company entered into a Restricted Stock Agreement (the “RSA”) under the Company’s 2021 Equity Compensation Plan (the “Plan”) with Alex Tarrabain, the Company’s Chief Financial Officer and a member of its board of directors. Pursuant to the RSA, the Company granted Mr. Tarrabain 1,000,000 shares of the Company’s common stock under the Plan to vest immediately on the grant date.
On July 13, 2021, the Company entered into an RSA (the “Keane RSA”) with Patrick Keane. Pursuant to the Keane RSA, the Company granted Mr. Keane 200,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered was recognized on the grant date.
On July 13, 2021, the Company entered into an RSA (the “Scott RSA”) with Daniel Scott. Pursuant to the Scott RSA, the Company granted Mr. Scott 300,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered was recognized on the grant date.
From July 1, 2021 to August 12, 2021, the Company authorized the issuance of 18,873 shares of its common stock upon conversion of the principal amount due under 4 notes, to 4 persons. The aggregate principal amount of the notes prior to conversion was $30,196.80.
Results of Operations
We have incurred recurring losses and have not commenced revenue generating operations to date. Our expenses to date are primarily our general and administrative expenses and fees, costs and expenses related to acquisitions and operations. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.
The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $43,176,727 at June 30, 2021 and had no committed source of debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including a note that is in default and is secured by the Company’s equipment and certain unsecured convertible notes payable. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.
Results of Operations for the Three and Six-Months Ended June 30, 2021 and 2020:
The following tables reflect our operating results for the three and six-months ended June 30, 2021 and 2020, respectively:
| Three-months ended |
||||||||||||
| Operating Summary |
June 30, 2021 |
June 30, 2020 |
Change |
|||||||||
| Revenues, net |
$ | - | $ | - | - | |||||||
| Cost of Goods Sold |
- | - | - | |||||||||
| Gross Profit |
- | - | - | |||||||||
| Operating Expenses |
(16,263,577 | ) | (690,447 | ) | 2,255.5 | % |
||||||
| Loss from Operations |
(16,263,577 | ) | (690,447 | ) | 2,255.5 | % |
||||||
| Other Income (Expense) |
770,412 | (969,434 | ) | (179.5 | %) |
|||||||
| Net Loss |
$ | (15,493,165 | ) | $ | (1,659,881 | ) | 833.4 | % |
||||
| Six-months ended |
||||||||||||
| Operating Summary |
June 30, 2021 |
June 30, 2020 |
Change |
|||||||||
| Revenues, net |
$ | - | $ | - | - | |||||||
| Cost of Goods Sold |
- | - | - | |||||||||
| Gross Profit |
- | - | - | |||||||||
| Operating Expenses |
(16,608,417 | ) | (1,221,197 | ) | 1,260.0 | % |
||||||
| Loss from Operations |
(16,608,417 | ) | (1,221,197 | ) | 1,260.0 | % |
||||||
| Other Income (Expense) |
492,217 | (1,738,796 | ) | (128.3 | %) |
|||||||
| Net Loss |
$ | (16,116,200 | ) | $ | (2,959,993 | ) | 444.5 | % |
||||
Revenue
We have not recognized revenue during the three or six-months ended June 30, 2021 and 2020, as we have not commenced revenue generating operations to date.
Operating Expenses
During the three months ended June 30, 2021, our operating expenses were $16,263,577 compared to $690,447 during the three months ended June 30, 2020. During the three months ended June 30, 2021, our operating expenses were comprised of salary and consulting fees of $943,800, stock-based compensation expense of $14,925,572, and general and administrative expenses of $394,205. By comparison, during the three months ended June 30, 2020, our operating expenses were comprised of salary and consulting fees of $193,200, stock-based compensation expense of $196,650, and general and administrative expenses of $300,597. Expenses incurred during the three months ended June 30, 2021 compared to three months ended June 30, 2020 increased primarily due to increased consulting fees for business coaching for our executives, increased stock-based compensation for our executives and board members as well as increases in legal and professional fees.
During the six months ended June 30, 2021, our operating expenses were $16,608,417 compared to $1,221,197 during the six months ended June 30, 2020. During the six months ended June 30, 2021, our operating expenses were comprised of salary and consulting fees of $975,000, stock-based compensation expense of $15,001,322, and general and administrative expenses of $632,095. By comparison, during the six months ended June 30, 2020, our operating expenses were comprised of salary and consulting fees of $224,477, stock-based compensation expense of $393,300, and general and administrative expenses of $603,420. Expenses incurred during the six months ended June 30, 2021 compared to six months ended June 30, 2020 increased primarily due to increased consulting fees for business coaching for our executives, increased stock-based compensation for our executives and board members as well as increases in legal and professional fees.
Other Income and Expense Items
During the three months ended June 30, 2021, our other income, net was $770,412 compared to other expense, net of $969,434 during the three months ended June 30, 2020. During the three months ended June 30, 2021, our other income and expense items were comprised of interest expense of $276,389, gain on change in fair value of patent acquisition liability of $1,078,000, and foreign exchange loss of $31,199. By comparison, during the three months ended June 30, 2020, our other income and expense items were comprised of interest expense of $906,524, interest income of $1,853, and foreign exchange loss of $64,763. Expenses incurred during the three months ended June 30, 2021 compared to three months ended June 30, 2020 decreased primarily due to a decrease in interest expense as a result of debt conversions and a favorable change in the fair value of the patent acquisition liability.
During the six months ended June 30, 2021, our other income, net was $492,217 compared to other expense, net of $1,738,796 during the six months ended June 30, 2020. During the six months ended June 30, 2021, our other income and expense items were comprised of interest expense of $530,253, interest income of $394, gain on change in fair value of patent acquisition liability of $1,078,000, and foreign exchange loss of $55,924. By comparison, during the six months ended June 30, 2020, our other income and expense items were comprised of interest expense of $1,806,655, interest income of $3,912, and foreign exchange gain of $63,947. Expenses incurred during the six months ended June 30, 2021 compared to six months ended June 30, 2020 decreased primarily due to a decrease in interest expense as a result of debt conversions and a favorable change in the fair value of the patent acquisition liability.
Income Taxes
As of June 30, 2021, the Company has net operating loss carryforwards of approximately $28,900,000 that may be available to reduce future years’ taxable income. As of June 30, 2021, the Company has a deferred tax asset of approximately $7,600,000 which has been completely offset by a valuation allowance. The Company believes that it is more likely than not that the carryforwards will expire unused as the Company has not been able to commence revenue generating activities to date.
Net Loss
Our net loss during the three months ended June 30, 2021 was $15,493,165 compared to a net loss of $1,659,881 during the three months ended June 30, 2020 due to the factors discussed above.
Our net loss during the six months ended June 30, 2021 was $16,116,200 compared to a net loss of $2,959,993 during the six months ended June 30, 2020 due to the factors discussed above.
Liquidity and Capital Resources
As of June 30, 2021 and December 31, 2020, our liquid assets consisted of cash of $10,840 and $1,908, respectively.
As of June 30, 2021, our indebtedness includes a patent acquisition liability of $302,000, accrued interest of $1,295,080, accrued interest to related parties of $1,720,575, as well as loans payable, loans payable to related parties, convertible notes and convertible notes to related parties at original issuance totaling $6,694,937 ($6,659,386 net of debt discount), with maturity dates as outlined below. The convertible notes are generally due 2 years from issuance with notes maturing in 2018 through 2023. As of August 12, 2021 we are currently in default of $5,148,410 of unsecured debt. We expect our operating and administrative expenses to be at least $1,200,000 annually.
| Description |
Maturity Date |
Amount at Original Issuance |
||||
| Loan Payable |
Q2 2016 |
$ | 75,000 | |||
| Loan Payable |
Q2 2018 |
10,000 | ||||
| Loan Payable |
Q1 2019 |
53,000 | ||||
| Loan Payable |
Q4 2019 |
45,000 | ||||
| Loan Payable |
Q1 2020 |
32,000 | ||||
| Loan Payable |
Q3 2020 |
370,618 | ||||
| Loan Payable |
Q2 2021 |
50,000 | ||||
| Loan Payable – Related Party |
12/31/2018 |
839,395 | ||||
| Loan Payable – Related Party |
10/2/2019 | 300,000 | ||||
| Loan Payable – Share Interest |
8/16/2021 |
150,000 | ||||
| Loan Payable – Share Interest – Related Party |
8/16/2021 |
175,000 | ||||
| Convertible Notes |
On Demand |
891,282 | ||||
| Convertible Notes |
Q2 2018 |
4,000 | ||||
| Convertible Notes |
Q4 2018 |
50,000 | ||||
| Convertible Notes |
Q1 2019 |
137,072 | ||||
| Convertible Notes |
Q2 2019 |
220,000 | ||||
| Convertible Notes |
Q3 2019 |
75,197 | ||||
| Convertible Notes |
Q4 2019 |
113,600 | ||||
| Convertible Notes |
Q1 2020 |
122,800 | ||||
| Convertible Notes |
Q2 2020 |
6,000 | ||||
| Convertible Notes |
Q3 2020 |
163,395 | ||||
| Convertible Notes |
Q4 2020 |
7,000 | ||||
| Convertible Notes |
Q1 2021 |
11,047 | ||||
| Convertible Notes |
Q2 2021 |
75,000 | ||||
| Convertible Notes |
Q3 2021 |
26,320 | ||||
| Convertible Notes |
Q4 2021 |
201,360 | ||||
| Convertible Notes |
Q2 2022 |
30,565 | ||||
| Convertible Notes |
Q3 2022 |
24,000 | ||||
| Convertible Notes - Related Party |
Q1 2019 |
878,368 | ||||
| Convertible Notes - Related Party |
Q3 2020 |
1,509,918 | ||||
| Convertible Notes - Related Party |
Q2 2022 |
48,000 | ||||
| Total |
$ | 6,694,937 | ||||
We intend to fund our expenses through the issuance and sale of additional securities. We do not have any commitments from any persons to purchase any securities and there can be no assurance that we will be able to raise sufficient funds to pay our liabilities as they become due and payable.
Six-months ended June 30, 2021 and 2020
Cash Flows from Operating Activities
We have not generated positive cash flows from operating activities. During the six months ended June 30, 2021, we used $277,463 in operating activities compared to $245,317 used in operating activities during the six months ended June 30, 2020. The increase in the use of operating cash between the two periods was primarily related to increases in general and administrative expenses in conjunction with increases in cash paid for interest.
Cash Flows from Investing Activities
Our use of cash flow for investing activities during the six months ended June 30, 2021 was $120,000 compared to $0 during the six months ended June 30, 2020. During the six months ended June 30, 2021, our use of cash flows for investing activities was comprised of advances to CEN Biotech Ukraine of $120,000. By comparison, during the six months ended June 30, 2020, we did not have any cash flows from investing activities.
Cash Flows from Financing Activities
During the six months ended June 30, 2021, we received $456,395 through issuance of convertible notes to investors to fund our working capital requirements and repaid $50,000 of our loans payable. During the six months ended June 30, 2020, we received $250,000 through issuance of convertible notes to investors to fund our working capital requirements
During the six months ended June 30, 2021, holders of convertible notes totaling $4,923,861 elected to convert their notes into 3,332,680 common shares.
During the three-month period ended June 30, 2021, certain private investors elected to convert $78,893 of accrued interest owed on convertible notes into 94,357 shares of common stock.
CEN has no committed source of debt or equity financing. Our Executive team and Board are seeking additional financing from their business contacts, but no assurances can be given that such financing will be obtained or, if obtained, on what terms.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K, obligations under any guarantee contracts or contingent obligations. We also have no other commitments, other than the costs of being a reporting company that will increase our operating costs or cash requirements in the future.
Jumpstart Our Business Startups Act of 2012
The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company can take advantage of certain exemptions from various reporting and other requirements that are applicable to public companies that are not emerging growth companies. We currently take advantage of some, but not all, of the reduced regulatory and reporting requirements that are available to us for as long as we qualify as an emerging growth company. Our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting for as long as we qualify as an emerging growth company.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
No pronouncements were adopted by the Company during the quarter ended June 30, 2021.
Recent Accounting Pronouncements Not Yet Adopted
In August 2020, the Financial Accounting Standards Board (“FASB”) issued an accounting pronouncement (ASU 2020-06) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity's own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity's own equity. As a smaller reporting company, as defined by the SEC, this pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2023. The Company is currently evaluating the impact of this ASU on the consolidated financial statements.
Critical Accounting Policies
The preparation of condensed consolidated financial statements and related notes requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities.
An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the condensed consolidated financial statements.
Financial Reporting Release No. 60 requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. There are no critical policies or decisions that rely on judgments that are based on assumptions about matters that are highly uncertain at the time the estimate is made. Note 1 to the consolidated financial statements includes a summary of the significant accounting policies and methods used in the preparation of our condensed consolidated financial statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
As a smaller reporting company, we are not required to provide the information called for by this Item.
ITEM 4. CONTROLS AND PROCEDURES.
(a) Evaluation of disclosure and controls and procedures.
As of June 30, 2021, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an assessment and evaluated the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2021. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was effective as of June 30, 2021.
Management recognized the need for additional resources in the area of accounting and financial reporting controls and procedures. As a result, we have outsourced the accounting and financial reporting oversight roles to a qualified accounting firm with public company reporting expertise.
(b) Changes in internal control over financial reporting.
The Company has implemented a requirement to conduct a review with our legal and advisory CPA firm before making significant changes or engaging in new deals or actions. There were no other changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
From time to time, we may become party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings that we believe to be material or which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition or results of operation if determined adversely to us.
ITEM 1A. RISK FACTORS.
Not applicable.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
During the three and six-months ended June 30, 2021, CEN entered into loans and associated extension agreements with various parties and also settled accrued liabilities. In consideration for such loans and associated extensions, along with the settlement of accrued liabilities, CEN granted various individuals a total aggregate amount of 139,357 and 192,726 unregistered shares of common stock of CEN during the three and six-months ended June 30, 2021, respectively.
The above issuances of shares of common stock were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder or in reliance on the provisions of Regulation S promulgated thereunder.
During the three and six-months ended June 30, 2021, we issued $346,395 and $456,395, respectively, of convertible notes to investors to fund our working capital requirements. These notes bear interest at 5% per year and are convertible at the option of the holder into 609,025 and 677,775 common shares, respectively.
The above issuances of convertible notes were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder or in reliance on the provisions of Regulation S promulgated thereunder.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
CEN has a payment default with respect to certain unsecured loans payable to private investors and related parties, in the principal amount of $1,775,013 and which bear interest at rates from 5% to 22% per annum which were due prior to August 12, 2021. The aggregate amounts due under these loans as of August 12, 2021, including accrued interest, is approximately $2,876,000. Interest and default interest and related fees currently accrue at approximately $47,000 per quarter.
CEN has a payment default with respect to certain unsecured convertible loans payable to private investors and related parties, in the principal amount of $3,373,398 and which bear interest at 5% per annum which were due prior to August 12, 2021. The aggregate amounts due under these loans as of August 12, 2021, including accrued interest, is approximately $4,649,000. Interest and default interest and related fees currently accrue at approximately $42,000 per quarter.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.
ITEM 6. EXHIBITS.
The exhibits listed on the Exhibit Index below are provided as part of this report.
| Exhibit No. |
Description |
| 3.1 |
|
| 3.2 |
|
| 31.1 |
|
| 31.2 |
|
| 32.1 |
|
| 32.2 |
______
| 101.INS |
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).* |
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document.* |
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document.* |
| 101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document.* |
| 101.LAB |
Inline XBRL Taxonomy Extension Labels Linkbase Document.* |
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document.* |
| 104 |
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).* |
_____________
* Filed herewith.
b. Financial Statement Schedules
None
SIGNATURES
Pursuant to the requirements of Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: August 12, 2021
| CEN BIOTECH, INC. |
|||
| By: |
/s/ Bahige Chaaban |
||
| Name: |
Bahige Chaaban |
||
| Title: |
Chief Executive Officer (Principal Executive Officer) |
||
| /s/ Alex Tarrabain | |||
| Dated: August 12, 2021 | Name: Alex Tarrabain | ||
| Title: Chief Financial Officer (Principal Financial and Accounting Officer) | |||
Exhibit 31.1
CERTIFICATIONS
I, Bahige Chaaban, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, of CEN Biotech Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 12, 2021 |
|
|
|
|
|
|
/s/ Bahige Chaaban |
|
|
|
|
Bahige Chaaban Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
Exhibit 31.2
CERTIFICATIONS
I, Alex Tarrabain, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, of CEN Biotech Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: August 12, 2021 |
/s/Alex Tarrabain | |
|
Alex Tarrabain Chief Financial Officer (Principal Financial Officer) |
||
Exhibit 32.1
Section 1350 Certification
In connection with the Quarterly Report on Form 10-Q of CEN Biotech Inc. (the “Company”) for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Bahige Chaaban, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
Date: August 12, 2021 |
/s/ Bahige Chaaban |
|
|
Bahige Chaaban Chief Executive Officer (Principal Executive Officer) |
||
Exhibit 32.2
Section 1350 Certification
In connection with the Quarterly Report on Form 10-Q of CEN Biotech Inc. (the “Company”) for the quarter ended June 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Alex Tarrabain, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
Date: August 12, 2021 |
/s/Alex Tarrabain |
|
|
Alex Tarrabain, Chief Financial Officer (Principal Financial Officer) |
||
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands |
6 Months Ended | 12 Months Ended |
|---|---|---|
Jun. 30, 2021 |
Dec. 31, 2020 |
|
| Common stock, par value (in dollars per share) | $ 0 | $ 0 |
| Common stock, shares issued (in shares) | 43,142,060 | 27,557,363 |
| Common stock, shares outstanding (in shares) | 43,142,060 | 27,557,363 |
| Common stock, authorized | Unlimited | Unlimited |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
|
| Operating expenses | ||||
| Consulting fees | $ 897,000 | $ 162,000 | $ 897,000 | $ 162,077 |
| Consulting fees – related parties | 46,800 | 31,200 | 78,000 | 62,400 |
| Stock based compensation | 14,925,572 | 196,650 | 15,001,322 | 393,300 |
| General and administrative | 394,205 | 300,597 | 632,095 | 603,420 |
| Total operating expenses | 16,263,577 | 690,447 | 16,608,417 | 1,221,197 |
| Loss from operations | (16,263,577) | (690,447) | (16,608,417) | (1,221,197) |
| Other income (expense) | ||||
| Interest expense | (162,975) | (800,465) | (293,603) | (1,595,145) |
| Interest expense – related parties | (113,414) | (106,059) | (236,650) | (211,510) |
| Interest income | 0 | 1,853 | 394 | 3,912 |
| Change in fair value of patent acquisition liability | 1,078,000 | 0 | 1,078,000 | 0 |
| Foreign exchange (loss) gain | (31,199) | (64,763) | (55,924) | 63,947 |
| Other income (expense), net | 770,412 | (969,434) | 492,217 | (1,738,796) |
| Net loss | $ (15,493,165) | $ (1,659,881) | $ (16,116,200) | $ (2,959,993) |
| Net loss per share: | ||||
| Basic and diluted (in dollars per share) | $ (0.38) | $ (0.06) | $ (0.47) | $ (0.11) |
| Weighted average number of shares outstanding | ||||
| Basic and diluted (in shares) | 40,591,815 | 27,207,044 | 34,194,612 | 27,091,577 |
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] |
NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the condensed consolidated financial statements of the Company for the year ended December 31, 2020 and notes thereto.
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
Loss per Share
Net loss per common share is computed pursuant to ASC 260-10-45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three and six-months ended June 30, 2021 and 2020, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.
Recent Developments
In April of 2021, the Company’s common stock began to be quoted on the OTC Link alternative trading system (operated by OTC Markets Group Inc.) under the trading symbol “CENBF” on the OTC Pink tier. There is no assurance that an active trading market for our shares will develop or will be sustained if developed.
On April 19, 2021, the Board appointed Mr. Bahige (Bill) Chaaban to serve as Chief Executive Officer of the Company effective April 19, 2021. On the same date, the Board appointed Mr. Joseph Byrne to serve as President and a member of the Board of the Company effective April 19, 2021. On the same, date, the Board appointed Mr. Rick Purdy to serve as a member of the Board of the Company effective April 19, 2021. On the same date, the Board appointed Mr. Jeffrey Thomas to serve as a member of the Board of the Company effective April 19, 2021.
On April 20, 2021, the Company entered into a Share Exchange Agreement (the “Agreement”) with Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), each of the shareholders of CCM as set forth on the signature pages of the Agreement (the “CCM Shareholders”) and Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”, each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties”). Pursuant to the Agreement, the Company agreed to acquire from the CCM Shareholders, all of the common shares of CCM, which is 10,000 shares of CCM common shares (the “CCM Stock”) held by the CCM Shareholders in exchange (the “Exchange”) for the issuance by the Company to the CCM Shareholders of 4,000,000 restricted shares of the Company’s common stock, no par value per share (the “Company Common Stock”). The Agreement closed on July 9, 2021 (the “Closing”). At Closing, the CCM Shareholders delivered the CCM Stock to the Company and the Company delivered the Company Common Stock to the CCM Shareholders, and CCM became a wholly owned subsidiary of the Company.
At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one and to appoint and named the Shareholder Representative as a member of the Board of the Company. Additionally, at Closing, the Company appointed and named the Shareholder Representative as the Company’s Chief Technology Officer.
At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $31,200.
Recently Adopted Accounting Pronouncements
No pronouncements were adopted by the Company during the six-month period ended June 30, 2021.
Recent Accounting Pronouncements Not Yet Adopted
In August 2020, the Financial Accounting Standards Board (“FASB”) issued an accounting pronouncement (ASU 2020-06) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity's own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity's own equity. As a smaller reporting company, as defined by the SEC, this pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2023. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. |
Note 2 - Going Concern Uncertainty / Management Plans |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Substantial Doubt about Going Concern [Text Block] |
NOTE 2 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS
The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $43,176,727 at June 30, 2021 and had no committed source of additional debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including notes that are in default, as described in Notes 5, 6, 7, and 8. The Company will continue to raise additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. The COVID-19 pandemic has hindered the Company’s ability to raise capital. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue. |
Note 3 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Advances to Related Party [Text Block] |
NOTE 3 – ADVANCES TO CEN BIOTECH UKRAINE AND LOAN RECEIVABLE FROM EMERGENCE GLOBAL
At December 31, 2020, the Company had an outstanding loan receivable of $17,901 from Emergence Global Enterprises Inc. (“Emergence Global”), a related party (see Note 11). The loan was made for the purpose of funding the operations of Emergence Global. The loan was unsecured, non-interest bearing, and was due on December 31, 2021. At the time the loan was made, Joseph Byrne, the CEO of Emergence Global was not an officer or director of the Company. He was at that time a 5% shareholder and former CEO of the Company. He was then appointed as the President and a director of the Company on April 19, 2021. Additionally, our CEO, Bill Chaaban was appointed as the President of Emergence Global on April 12, 2021. In light of Section 402 of the Sarbanes-Oxley Act of 2002, the Company and Emergence Global entered into that certain Loan Repayment Agreement dated as of May 6, 2021, pursuant to which Emergence Global agreed to repay to the Company $17,901, representing the total amount outstanding under the loan agreement, by issuing 21,830 shares of Emergence Global common stock, $0.82 par value per share. Such shares were issued to the Company on May 6, 2021. As the value of the common shares is not material, it has been presented within prepaid expenses and other assets.
At June 30, 2021 and December 31, 2020, the Company had advances of $1,299,328 and $1,179,328, respectively, to CEN Biotech Ukraine, LLC, a related party (see Note 11). The advances were for the purpose of funding the operations of CEN Biotech Ukraine, LLC.
Bahige (Bill) Chaaban, our Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not currently hold any positions with CEN Ukraine. CEN Ukraine is operated and controlled by its sole director. Pursuant to Ukrainian law, shareholders of a company do not have the ability to control the company or the actions of its director. CEN Ukraine is operated under the direction of its management pursuant to the guidelines of Ukrainian law. These loans are unsecured, non-interest bearing, and are due on demand.
|
Note 4 - Intangible Assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets Disclosure [Text Block] |
NOTE 4 – INTANGIBLE ASSETS
On September 12, 2016, the Company executed an agreement dated August 31, 2016, to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian Corporation, and Stevan (Steve) Pokrajac (the “Sellers”).
Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 million upon commencement of public trading (b) The transfer of real properties located at 135 North Rear Road, Lakeshore, Ontario, Canada having a fair value of $2,161,467 and 1517-1525 Ridge Road having a purchase cost (including other related disbursements) to the Company of $202,666.
The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 between the Company and the Sellers, CEN has reaffirmed the rights to use the patented technology.
In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not yet been formed, in connection with the development of the acquired technology with compensation equal to $200,000 per year, commencing with the start of operations.
In March 2018, the Tesla agreement was amended to replace the $5 million stock consideration commitment with a commitment to issue one million registered shares of CEN common stock with a closing date of September 30, 2018. On October 4, 2018, this agreement was amended to extend the closing date to December 15, 2018. On April 3, 2019, the Company entered into an amendment which extended the closing date of the agreement to December 31, 2019. On March 16, 2020 the Company entered into an amendment extending the closing date until December 31, 2021. The March 2018 modification of the agreement converted a fixed value of shares to a fixed number of shares. Accordingly, the liability was reduced and additional paid in capital was increased by $4,380,000 to reflect the fair value of the shares committed at the date of the amendment. As of June 30, 2021 and December 31, 2020, the value of this liability was $302,000 and $1,380,000, respectively. This liability will be remeasured at each reporting date using the current fair value of CEN’s common shares.
The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no fair value.
The intangible asset consists of the following at:
As of June 30, 2021 and December 31, 2020, there is no impairment expense recognized based on the Company’s expectations that it will be able to monetize the patent. The lighting patent is being amortized straight-line over 16 years. Expected amortization expense is $424,812 per year through 2031, with the remaining $283,215 to be amortized in 2032. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 5 - Loans Payable |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Short-term Debt [Text Block] |
NOTE 5 – LOANS PAYABLE
Loans payable consist of the following at:
During each of the three-month periods ended June 30, 2021 and 2020, 18,000 common shares were issued to individuals in connection with interest terms of the above loans. Accordingly, during the three-month periods ended June 30, 2021 and 2020, $16,500 and $12,960 in interest expense and additional paid-in capital was recorded, respectively.
During each of the six-month periods ended June 30, 2021 and 2020, 36,000 common shares were issued to individuals in connection with interest terms of the above loans. Accordingly, during the six-month periods ended June 30, 2021 and 2020, $41,340 and $25,920 in interest expense and additional paid-in capital was recorded, respectively.
During the three-month period ended June 30, 2021, certain private investors amended their convertible notes payable totaling $250,000, which were convertible into 128,125 common shares. As a result of the amendments, these notes no longer contain a conversion feature and have been reclassified to loans payable from convertible notes payable.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 6 - Loans Payable - Related Party |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Loans Payable to Related Party [Text Block] |
NOTE 6 – LOANS PAYABLE- RELATED PARTY
Loans payable - related party consists of the following at:
Attributable related party accrued interest was $617,832 and $568,969 as of June 30, 2021 and December 31, 2020, respectively. Interest expense attributable to related party loans was $51,662 and $46,188 for the three-months ended June 30, 2021 and 2020, respectively, and was $115,524 and $91,771 for the six-months ended June 30, 2021 and 2020, respectively.
During both three-month periods ended June 30, 2021 and 2020, 27,000 common shares were issued to related parties in connection with interest terms of the above loans made to CEN. Accordingly, during the three-month periods ended June 30, 2021 and 2020, $24,750 and $19,440 in related party interest expense and additional paid-in capital was recorded, respectively.
During both six-month periods ended June 30, 2021 and 2020, 54,000 common shares were issued to related parties in connection with interest terms of the above loans made to CEN. Accordingly, during the six-month periods ended June 30, 2021 and 2020, $62,010 and $38,880 in related party interest expense and additional paid-in capital was recorded, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 7 - Convertible Notes |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Long-term Debt [Text Block] |
NOTE 7 – CONVERTIBLE NOTES
Convertible notes payable consists of the following at:
The Company issues convertible notes as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance. The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued during both the three and six-month periods ended June 30, 2021 to be $93,164. This value has been recorded as a component of equity during 2021 and the aggregate original issue discount is accreted and charged to interest expense as a financing expense from the date of issuance until maturity. Upon conversion, any remaining unaccreted discount is charged to interest expense. No convertible notes with beneficial conversion features were issued during the three or six-month periods ended June 30, 2020.
These notes may be converted at the option of the note holder upon written notice by the note holder. These notes are convertible into a total of 1,204,177 common shares.
During the three-month period ended June 30, 2021, certain private investors elected to exercise their convertible notes payable totaling $4,855,861 in exchange for 3,290,180 common shares. As a result, the associated convertible notes have been extinguished and reclassified as additional paid in capital.
During the three-month period ended June 30, 2021, certain private investors elected to convert $78,893 of accrued interest owed on convertible notes into 94,357 shares of common stock.
As of August 12, 2021, we are currently in default of $985,111 of convertible notes payable, which are convertible into 619,167 shares of common stock. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 8 - Convertible Notes Payable - Related Parties |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Long-term Convertible Notes Related Party [Text Block] |
NOTE 8 – CONVERTIBLE NOTES PAYABLE - RELATED PARTIES
Convertible notes payable - related parties consists of the following at:
Attributable related party accrued interest was $1,102,743 and $1,046,911 as of June 30, 2021 and December 31, 2020, respectively. Interest expense attributable to related party convertible notes was $61,752, and $59,871 for the three months ended June 30, 2021 and 2020, respectively, and was $121,126 and $119,739 for the six-months ended June 30, 2021 and 2020, respectively.
The Company issues convertible notes to related parties as a method to raise operating capital. These notes convert to a fixed number of shares specified in the convertible note, at the option of the note holder. Certain of these notes are considered to contain a beneficial conversion feature if in-the-money at the time of issuance.
The Company has determined the value associated with the beneficial conversion feature in connection with the notes issued to related parties during both the three and six-month periods ended June 30, 2021 to be $18,142. This value has been recorded as a component of equity during 2021 and the aggregate original issue discount is accreted and charged to interest expense as a financing expense from the date of issuance until maturity. Upon conversion, any remaining unaccreted discount is charged to interest expense. No convertible notes to related parties with beneficial conversion features were issued during the three or six-month periods ended June 30, 2020.
These notes may be converted at the option of the note holder upon written notice by the note holder. These notes are convertible into a total of 1,587,167 common shares.
During the three-month period ended June 30, 2021, a convertible note due to Joseph Byrne in the amount of $102,395, convertible into 63,997 shares, was transferred to a private investor and reclassified.
As of August 12, 2021, we are currently in default of $2,388,287 of convertible notes payable, which are convertible into 1,492,679 shares of common stock. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 9 - Income Taxes |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Tax Disclosure [Text Block] |
NOTE 9 – INCOME TAXES
A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three and six-months ended June 30:
As of June 30, 2021, the Company has net operating loss carry forwards of approximately $28,900,000 that may be available to reduce future years’ taxable income. Such carry forwards typically expire after 20 years. The Company currently has carry forwards that begin to expire in 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these consolidated financial statements, because the Company believes that it is more likely than not that the carryforwards will expire unused and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and associated valuation allowance are as follows for the period ended June 30, 2021 and the year ended December 31, 2020:
The valuation allowance increased $4,100,000 and $600,000 for the three-months ended June 30, 2021 and 2020, respectively, and $4,200,000 and $700,000 for the six-months ended June 30, 2021 and 2020, respectively. All other temporary differences are immaterial both individually and in the aggregate to the condensed consolidated financial statements.
Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of June 30, 2021, there are no uncertain income tax positions taken or expected to be taken that would require recognition of a liability or disclosure in the condensed consolidated financial statements. The Company is subject to routing audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. Generally, the Company is no longer subject to income tax examinations for years prior to 2017. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Shareholders' Deficit / Stock Activity |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Stockholders' Equity Note Disclosure [Text Block] |
NOTE 10 – SHAREHOLDERS’ DEFICIT / STOCK ACTIVITY
The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value.
As of June 30, 2021, 2,791,344 shares of common stock are committed to the holders of the convertible notes. |
Note 11 - Related Party Transactions |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related Party Transactions Disclosure [Text Block] |
NOTE 11 – RELATED PARTY TRANSACTIONS
The Company has received loans from several related parties, as described above in Notes 6 and 8.
A loan totaling $17,901 was made to Emergence Global as of December 31, 2020. The loan was made for the business purpose of assisting Emergence with operating expenses. Emergence Global’s Chief Executive Officer is Joseph Byrne, a 5% shareholder and former CEO, and current President and member of the board of CEN. Joseph Byrne, previously served as the Chief Executive Officer and member of the Board of Directors of the Company from July 2017 until November 13, 2019. This note was repaid on May 6, 2021, see Note 3.
There are advances of $1,299,328 and $1,179,328 to CEN Biotech Ukraine as of June 30, 2021 and December 31, 2020, respectively. Such advances were made for the purpose of funding the operations of CEN Ukraine as summarized in Note 4. CEN Ukraine was founded by Bill Chaaban. Prior to December 3, 2017, Bill Chaaban directly owned 51% of CEN Ukraine. CEN Ukraine was founded to seek agricultural and pharmaceutical opportunities in Ukraine. Bill Chaaban personally funded the establishment and initial phases of CEN Ukraine. On December 14, 2017, the Company entered into a controlling interest purchase agreement with Bill Chaaban, our Chief Executive Officer and member of our board of directors, and another shareholder of CEN Ukraine, Usamakh Saadikh, a member of our board of directors, for 51% of the outstanding equity interests of CEN Ukraine. The consideration will be paid by issuing common shares of the Company. The agreement, which is subject to certain conditions, has not closed as of August 12, 2021, as the Company needs to raise additional funds in order to proceed with the closing. Bahige (Bill) Chaaban, our Chief Executive Officer and member of our Board of Directors, and Usamakh Saadikh, a member of our Board of Directors, each directly own 25.5% of CEN Ukraine respectively. The remaining 49% of CEN Ukraine is owned by XN Pharma, which is an entity jointly owned by Bahige (Bill) Chaaban and Usamakh Saadikh. Bahige (Bill) Chaaban and Usamakh Saadikh do not currently hold any positions with CEN Ukraine. CEN Ukraine is operated and controlled by its sole director. Pursuant to Ukrainian law, shareholders of a company do not have the ability to control the company or the actions of its director. CEN Ukraine is operated under the direction of its management per the guidelines of Ukrainian law.
On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at 5% per annum and are convertible to common shares with various maturity dates. They became related parties when they were elected.
During the three-months ended June 30, 2021 and 2020, the Company incurred payroll and consulting expenses of $46,800 and $31,200, respectively, and $78,000 and $62,400 during the six-months ended June 30, 2021 and 2020, respectively, with certain Board Members and Officers. As of June 30, 2021 and December 31, 2020, $408,200 and $330,200, respectively, was payable to these related parties for payroll and consulting charges, which are included within accrued expenses.
During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $300,000 note payable. This equipment was then sold to CEN Ukraine for a loss of $255,141 in exchange for a $44,859 note receivable, payable in 10 equal installments beginning in 2017 through 2026. No payments have been received as of June 30, 2021, however, management expects this balance to be collectible.
Jamaal Shaban (“Lessor”), cousin of Bill Chaaban, leased 20 North Rear Road, a 10.4 acre site of land in Canada which included two buildings and a security vault, to the Company under an agreement effective January 2017 for monthly rental payments of CAD 4,000 plus taxes for a period of years. This lease was assigned by the Lessor to Jamsyl Group, a third-party, when Jamsyl Group purchased the property from Jamaal Shaban in October 2019. Effective August 1, 2020, the Company entered into a mutual termination and release agreement with Jamsyl Group in exchange for 36,500 shares of CEN common stock, valued at $50,700, which vested immediately, based upon remaining lease payments owed. The lease had been accounted for as an operating lease utilizing an 8% discount rate. All remaining associated right-of-use assets as of August 1, 2020 of $48,110 and associated liabilities of $45,118 were written off in conjunction, resulting in a loss on lease termination of $53,692. During the three and six-months ended June 30, 2020, lease expenses of $8,690 and $17,409, respectively, related to this agreement were recognized within general and administrative expenses.
The Company also leased office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. This lease was subsequently assigned to RN Holdings Ltd, a third-party, on May 8, 2019 when RN holdings purchased the building. Under the lease agreement effective October 1, 2017, monthly rents of CAD 2,608 are due through September 2022, at which point monthly rents of CAD 3,390 are due. Effective August 1, 2020, the Company ceased making payments and abandoned the leased space. Accordingly, the Company determined that there was no future economic value to the associated right-of-use asset and recognized a full impairment loss of $146,795 on August 1, 2020. As of August 12, 2021, the Company has not reached an agreement with RN Holdings Ltd to modify or to settle the remaining contractual liability, which therefore remains recorded as of June 30, 2021 under its original contractual terms. The associated liability as of June 30, 2021 and December 31, 2020 was $175,746 and $164,997, respectively, utilizing an 8% discount rate. During the three-months ended June 30, 2021 and 2020, lease expenses of $5,577 and $6,928, respectively, and during the three-months ended June 30, 2021 and 2020, lease expenses of $10,749 and $13,253, respectively, related to this agreement were recognized within general and administrative expenses.
Effective with the August 1, 2020 lease termination and abandonments, all property, plant, and improvements, which were located at these properties were abandoned.
Maturities of the operating lease liability for the 12 months subsequent to June 30, 2021 was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 12 - Stock Based Compensation |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Text Block] |
NOTE 12 – STOCK BASED COMPENSATION
Adoption of Equity Compensation Plan
On November 29, 2017, the Board adopted the 2017 Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved 20,000,000 shares of common stock for issuance under the Plan. The Plan is intended to provide equity incentives to persons retained by our Company.
On April 2, 2021, the Board of Directors of the Company adopted the 2021 Equity Compensation Plan (the “2021 Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants of the Company and reserved an additional 20,000,000 shares of the Company’s common stock for issuance under the 2021 Plan.
Equity Compensation Grants
On November 30, 2017, the Company granted a one-time equity award (“Equity Award”) of restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement to certain executives and directors of the company. Donald Strilchuck, Director, received 1,000,000 restricted shares of the Company's common stock for security consulting services, of which 550,000 vested immediately and the remaining vesting ratably each month over the next 36 months. Other individuals received a total of 1,870,000 restricted shares of the Company's common stock for consulting services performed, of which 1,330,000 vested immediately and the remaining vesting ratably each month over the next 36 months. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.
On October 1, 2019, the Company entered into an agreement with a communications and branding firm for the payment of its services under which the Company issued 50,000 shares of its common stock. This award vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.
On April 17, 2020, the Company entered into agreements with three individuals for the payment of business consulting services under which the Company issued 225,000 shares of its common stock. These awards vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered of $162,000 was recognized on the grant date.
On August 27, 2020 and September 25, 2020, the Company entered into agreements with two individuals for the payment of business consulting services under which the Company issued an aggregate of 162,500 shares of its common stock. These awards vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered of $117,000 was recognized on the grant date.
On April 2, 2021, a consulting agreement with CONFIEN SAS for business coaching was entered into for a period of 12 months. As payment for these services, 650,000 restricted shares, subject to applicable securities laws and regulations as set forth in the Restricted Stack Agreement, of the Company’s common stock were granted. Such shares vested immediately. The expense related to the restricted stock awarded to non-employees for services previously rendered of $897,000 was recognized on the grant date.
Employment Agreements
On November 30, 2017, employment agreements were entered into with four key members of management:
On May 16, 2019, the Board appointed Alex Tarrabain, one of the members of the Company’s Board to serve as the Company’s Chief Financial Officer and as one of the Vice Presidents of the Company effective May 21, 2019 (the “Effective Date”). Richard Boswell, who served as the Company’s Chief Financial Officer since July 2017, resigned from his position as the Company’s Chief Financial Officer as of the Effective Date, continues to serve in his position as the Company’s Senior Executive Vice President going forward focusing on the Company’s strategic activities and will also continue to serve as a member of the Company’s Board.
In conjunction with the above, on May 16, 2019, an employment agreement was entered into with Mr. Tarrabain:
On April 2, 2021, the Board of Directors appointed Ameen Ferris and Harold Aubrey De Lavenu to serve as Vice Presidents of the Company. Under the associated Executive Employment Agreements, they will each receive compensation in the form of a base annual salary of $31,200. In addition, Ameen Ferris was granted 1,000,000 and Harold Aubrey De Lavenu was granted 1,041,250 restricted shares, subject to applicable securities laws and regulations, as set forth in the Restricted Stock Agreement, of the Company’s common stock. Such shares vested immediately. The expense related to the restricted stock awarded to employees for services previously rendered of $2,816,925 was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Boswell RSA”) with Richard Boswell. Pursuant to the Boswell RSA, the Company granted Mr. Boswell 2,185,679 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $3,016,237 was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Chaaban RSA”) with Bahige Chaaban. Pursuant to the Chaaban RSA, the Company granted Mr. Chaaban 3,106,122 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $4,286,435 was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Payne RSA”) with Brian Payne. Pursuant to the Payne RSA, the Company granted Mr. Payne 1,435,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $1,980,300 was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Saadikh RSA”) with Usamakh Saadikh. Pursuant to the Saadikh RSA, the Company granted Mr. Saadikh 1,000,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $1,380,000 was recognized on the grant date.
On April 2, 2021, the Company entered into an RSA (the “Strilchuck RSA”) with Donald Strilchuck. Pursuant to the Strilchuck RSA, the Company granted Mr. Strilchuck 341,250 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $470,925 was recognized on the grant date.
On April 2, 2021 and June 25, 2021, the Company entered into an RSA (the “Tarrabain RSA”) with Alex Tarrabain. Pursuant to the Tarrabain RSA, the Company granted Mr. Tarrabain 300,000 and 1,000,000, respectively, restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered of $899,000 was recognized on the grant date.
Restricted Stock Awards
Restricted stock awards relate to common shares that are subject to applicable securities laws and regulations as set forth in the RSAs and other equity compensation grants.
The total grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $28,760,063 and $13,013,241 as of June 30, 2021 and December 31, 2020, respectively. During the three and six-month periods ended June 30, 2021, 12,059,291 restricted shares with a grant date fair value of $15,746,822 were awarded. During the three and six-month periods ended June 30, 2020, 225,000 restricted shares with a grant date fair value of $162,000 were awarded. Prior to the start of trading on April 5, 2021 via the OTC Link alternative trading system (operated by OTC Markets Group Inc.), the grant-date fair value was calculated utilizing an enterprise valuation model as of the date the awards are granted. Beginning April 5, 2021, the grant-date fair value is calculated utilizing the daily closing price as published via the OTC Link.
With the exception of immediately vesting portions of awards, shares typically vest pro-rata over the requisite service period, which is generally years from the grant-date. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.
During the three-month periods ended June 30, 2021 and 2020, 12,134,291 and 900,000, respectively, and during the six-month periods ended June 30, 2021 and 2020, 12,209,291 and respectively, of these shares vested. The fair value of the restricted stock which vested amounted to $15,822,572 and $459,000 for the three-months ended June 30, 2021 and 2020, respectively, and $15,898,322 and $697,500 for the six-months ended June 30, 2021 and 2020, respectively.
Compensation expense recognized in connection with the restricted stock awards was $14,925,572 and $196,650 for the three-months ended June 30, 2021 and 2020, respectively, and $15,001,322 and $393,300 for the six-months ended June 30, 2021 and 2020, respectively. Consulting expense recognized in connection with the restricted stock awards was $897,000 and $162,000 for the three and six-months ended June 30, 2021 and 2020, respectively.
Non-vested restricted stock award activity for the six-months ended June 30, 2021 and 2020 are as follows:
The fair value of the restricted stock grants was based on the valuation of a third-party specialist prior to April 5, 2021. Beginning April 5, 2021, the fair value of the restricted stock grants is based upon the daily closing price per the OTC Link. As of June 30, 2021, unrecognized compensation expense totaled $277,750, which will be recognized on a straight-line basis over the vesting period or requisite service period through May 2022. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 13 - Net Loss Per Share |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Text Block] |
NOTE 13 – NET LOSS PER SHARE
During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of June 30, 2021 and 2020. Common stock equivalents that were excluded for the three and six-month periods ended June 30, 2021 and 2020 are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Note 14 - Contingency |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Commitments and Contingencies Disclosure [Text Block] |
NOTE 14 – CONTINGENCY
In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.
|
Note 15 - Fair Value Disclosures |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Text Block] |
NOTE 15 – FAIR VALUE DISCLOSURES
Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.
The fair value of the Company’s financial instruments are as follows at:
The fair values of other receivables (including related accrued interest), note receivable - CEN Biotech Ukraine, LLC, and advances to Emergence Global and CEN Biotech Ukraine, LLC approximate carrying value due to the terms of the instruments.
The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.
The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.
It is not practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.
The fair value of the patent acquisition liability is based upon the fair value of the common stock, which was obtained from a 3rd party valuation specialist prior to April 5, 2021. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies. Beginning April 5, 2021, the fair value of the patent acquisition liability is based upon the OTC closing price and accordingly was transferred from Level 3 to Level 1 due to the availability of published prices for CEN’s common stock. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 16 - Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Notes to Financial Statements | |
| Subsequent Events [Text Block] |
NOTE 16 – SUBSEQUENT EVENTS
From July 1, 2021 to August 12, 2021, the Company authorized the issuance of 18,873 shares of its common stock upon conversion of the principal amount due under 4 notes, to 4 persons. The aggregate principal amount of the notes prior to conversion was $30,196.80.
From July 1, 2021 to August 12, 2021, the Company issued 1 new convertible notes totaling $20,000 with conversion rights of 52,631 shares of the Company common stock.
On July 13, 2021, the Company entered into an RSA (the “Keane RSA”) with Patrick Keane. Pursuant to the Keane RSA, the Company granted Mr. Keane 200,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered was recognized on the grant date.
On July 13, 2021, the Company entered into an RSA (the “Scott RSA”) with Daniel Scott. Pursuant to the Scott RSA, the Company granted Mr. Scott 300,000 restricted shares of the Company’s common stock under the 2021 Plan to vest immediately on the grant date. The shares issued are restricted shares that are subject to applicable securities laws and regulations. The expense related to the restricted stock awarded to employees for services previously rendered was recognized on the grant date.
On April 20, 2021, the Company entered into a Share Exchange Agreement (the “Agreement”) with Clear Com Media Inc., an Ontario, Canada corporation (“CCM”), each of the shareholders of CCM as set forth on the signature pages of the Agreement (the “CCM Shareholders”) and Lawrence Lehoux as the Representative of the CCM Shareholders (the “Shareholders’ Representative”, each of CCM and the CCM Shareholders may be referred to collectively herein as the “CCM Parties”). Pursuant to the Agreement, the Company agreed to acquire from the CCM Shareholders, all of the common shares of CCM, which is 10,000 shares of CCM common shares (the “CCM Stock”) held by the CCM Shareholders in exchange (the “Exchange”) for the issuance by the Company to the CCM Shareholders of 4,000,000 restricted shares of the Company’s common stock, no par value per share (the “Company Common Stock”). The Agreement closed on July 9, 2021 (the “Closing”). At Closing, the CCM Shareholders delivered the CCM Stock to the Company and the Company delivered the Company Common Stock to the CCM Shareholders, and CCM became a wholly owned subsidiary of the Company. At Closing, the Company increased the number of members on its Board of Directors (the “Board”) by one and to appoint and named the Shareholder Representative as a member of the Board of the Company. Additionally, at Closing, the Company appointed and named the Shareholder Representative as the Company’s Chief Technology Officer. At Closing, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Lehoux. Pursuant to the Employment Agreement, during the term of the Employment Agreement, the Company agreed to employ, and Mr. Lehoux agreed to accept employment with the Company as the Company’s Chief Technology Officer. Pursuant to the Employment Agreement, the Company agreed to pay Mr. Lehoux an annual base salary of $31,200.
|
Significant Accounting Policies (Policies) |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Accounting Policies [Abstract] | |
| Earnings Per Share, Policy [Policy Text Block] | Loss per Share
Net loss per common share is computed pursuant to ASC 260-10-45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three and six-months ended June 30, 2021 and 2020, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.
|
| New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements
No pronouncements were adopted by the Company during the six-month period ended June 30, 2021.
Recent Accounting Pronouncements Not Yet Adopted
In August 2020, the Financial Accounting Standards Board (“FASB”) issued an accounting pronouncement (ASU 2020-06) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity's own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity's own equity. As a smaller reporting company, as defined by the SEC, this pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2023. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. |
Note 4 - Intangible Assets (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Finite-Lived Intangible Assets [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 5 - Loans Payable (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Short-term Debt [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 6 - Loans Payable - Related Party (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Loans Payable to Related Party [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 7 - Convertible Notes (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Long-term Debt Instruments [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 8 - Convertible Notes Payable - Related Parties (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Convertible Notes Payable to Related Party [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 9 - Income Taxes (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 11 - Related Party Transactions (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lessee, Operating Lease, Liability, Maturity [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 12 - Stock Based Compensation (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nonvested Restricted Stock Shares Activity [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 13 - Net Loss Per Share (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Note 15 - Fair Value Disclosures (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, by Balance Sheet Grouping [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) |
Jul. 09, 2021 |
Apr. 20, 2021 |
|---|---|---|
| Chief Technology Officer [Member] | Subsequent Event [Member] | ||
| Annual Salary | $ 31,200 | |
| Clear Com Media, Inc [Member] | ||
| Share Exchange Agreement, Shares to Acquire (in shares) | 10,000 | |
| Share Exchange Agreement, Shares to Issue (in shares) | 4,000,000 |
Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Retained Earnings (Accumulated Deficit), Ending Balance | $ (43,176,727) | $ (27,060,527) |
Note 3 - Advances to CEN Biotech Ukraine and Loan Receivable from Emergence Global (Details Textual) - USD ($) |
May 06, 2021 |
Jun. 30, 2021 |
Dec. 31, 2020 |
Dec. 02, 2017 |
|---|---|---|---|---|
| Notes Receivable, Related Parties, Current | $ 0 | $ 17,901 | ||
| Emergence Global [Member] | ||||
| Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.82 | |||
| Former CEO [Member] | ||||
| Ownership Percentage | 5.00% | |||
| CEN Biotech Ukraine [Member] | ||||
| Notes Receivable, Related Parties, Current | $ 17,901 | |||
| Due from Related Parties, Total | $ 1,299,328 | 1,179,328 | ||
| Percentage of Related Party's Equity Interest Owned by Director | 51.00% | |||
| CEN Biotech Ukraine [Member] | Usamakh Saadikh [Member] | ||||
| Ownership Percentage | 49.00% | |||
| Percentage of Related Party's Equity Interest Owned by Director | 25.50% | |||
| Emergence Global [Member] | ||||
| Notes Receivable, Related Parties, Current | $ 17,901 | |||
| Notes Receivable, Original Amount Converted to Common Stock | $ 17,901 | |||
| Notes Receivable, Converted Instrument, Shares Received as Payment (in shares) | 21,830 |
Note 4 - Intangible Assets - Intangible Assets (Details) - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Lighting patent | $ 6,797,000 | $ 6,797,000 |
| Accumulated amortization | (2,053,259) | (1,840,853) |
| Net | $ 4,743,741 | $ 4,956,147 |
Note 5 - Loans Payable (Details Textual) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2021
USD ($)
shares
|
Jun. 30, 2020
USD ($)
shares
|
Jun. 30, 2021
USD ($)
shares
|
Jun. 30, 2020
USD ($)
shares
|
|
| Stock Issued During Period, Value, New Issues | $ 41,250 | $ 32,400 | $ 103,350 | $ 64,800 |
| Short-term Loan Payable to Multiple Investors [Member] | ||||
| Convertible Debt, Total | $ 250,000 | $ 250,000 | ||
| Debt Instrument, Convertible, Number of Equity Instruments | 128,125 | |||
| Debt Instrument, Convertible, Beneficial Conversion Feature | $ 0 | |||
| Individual Lenders [Member] | ||||
| Stock Issued During Period, Shares, New Issues (in shares) | shares | 18,000 | 18,000 | 36,000 | 36,000 |
| Stock Issued During Period, Value, New Issues | $ 16,500 | $ 12,960 | $ 41,340 | $ 25,920 |
Note 5 - Loans Payable - Loans Payable (Details) - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Loan payable | $ 785,618 | $ 527,379 |
| Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
| Loan payable | 75,000 | 75,000 |
| Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
| Loan payable | 310,618 | 302,379 |
| Short-term Loan Payable to an Individual [Member] | ||
| Loan payable | 50,000 | 50,000 |
| Second Short-term Loan Payable to an Individual [Member] | ||
| Loan payable | 100,000 | 100,000 |
| Short-term Loan Payable to Multiple Investors [Member] | ||
| Loan payable | $ 250,000 | $ 0 |
Note 5 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($) |
6 Months Ended | 12 Months Ended |
|---|---|---|
Jun. 30, 2021 |
Dec. 31, 2020 |
|
| Short-term Loan Payable to Global Holdings International, LLC [Member] | ||
| Interest Rate | 15.00% | 15.00% |
| Maturity Date | Jun. 30, 2016 | Jun. 30, 2016 |
| Short-term Mortgage Payable to ARG & Pals, Inc. [Member] | ||
| Interest Rate | 22.00% | 22.00% |
| Maturity Date | Nov. 21, 2018 | Nov. 21, 2018 |
| Original Amount | $ 385,000 | $ 385,000 |
| Short-term Loan Payable to an Individual [Member] | ||
| Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 |
| Share Interest (in shares) | 2,000 | 2,000 |
| Second Short-term Loan Payable to an Individual [Member] | ||
| Maturity Date | Aug. 16, 2021 | Aug. 16, 2021 |
| Share Interest (in shares) | 4,000 | 4,000 |
| Short-term Loan Payable to Multiple Investors [Member] | ||
| Interest Rate | 5.00% | 5.00% |
| Maturity Date, start | Jun. 01, 2018 | Jun. 01, 2018 |
| Maturity Date, end | May 31, 2021 | May 31, 2021 |
Note 6 - Loans Payable - Related Party (Details Textual) - USD ($) |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
|
| Interest Expense, Related Party | $ 113,414 | $ 106,059 | $ 236,650 | $ 211,510 | |
| Stock Issued During Period, Value, New Issues | $ 41,250 | $ 32,400 | $ 103,350 | $ 64,800 | |
| Related Parties Lenders [Member] | |||||
| Stock Issued During Period, Shares, New Issues (in shares) | 27,000 | 27,000 | 54,000 | 54,000 | |
| Stock Issued During Period, Value, New Issues | $ 24,750 | $ 19,440 | $ 62,010 | $ 38,880 | |
| Loans Payable to Related Party [Member] | |||||
| Interest Payable, Related Party | 617,832 | 617,832 | $ 568,969 | ||
| Interest Expense, Related Party | $ 51,662 | $ 46,188 | $ 115,524 | $ 91,771 | |
Note 6 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Long-term Debt, Total | $ 1,314,395 | $ 1,363,354 |
| Bill Chaaban, President of Cen Biotech [Member] | ||
| Long-term Debt, Total | 237,895 | 236,854 |
| Creative Edge [Member] | ||
| Long-term Debt, Total | 601,500 | 601,500 |
| R&D Labs Canada, Inc [Member] | ||
| Long-term Debt, Total | 300,000 | 300,000 |
| Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | ||
| Long-term Debt, Total | 100,000 | 100,000 |
| Director, Alex Tarrabain [Member] | ||
| Long-term Debt, Total | 75,000 | 75,000 |
| Joseph Byrne [Member] | ||
| Long-term Debt, Total | $ 0 | $ 50,000 |
Note 7 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Long-term Debt, gross | $ 2,158,638 | $ 6,730,448 |
| Less unamortized debt discount | 19,248 | 0 |
| Long-term Debt, Total | 2,139,390 | 6,730,448 |
| Less current portion | 2,115,390 | 6,652,448 |
| Convertible notes payable, less current portion | 24,000 | 78,000 |
| Convertible Notes 1[Member] | ||
| Long-term Debt, gross | 891,282 | 867,641 |
| Convertible Notes 2 [Member] | ||
| Long-term Debt, gross | 1,236,794 | 5,862,807 |
| Convertible Notes 3 [Member] | ||
| Long-term Debt, gross | $ 30,562 | $ 0 |
Note 7 - Convertible Notes - Convertible Notes (Details) (Parentheticals) - Convertible Debt [Member] |
6 Months Ended | 12 Months Ended |
|---|---|---|
|
Jun. 30, 2021
CAD ($)
|
Dec. 31, 2020
CAD ($)
|
|
| Conversion Rights | 1,204,177 | |
| Convertible Notes 1[Member] | ||
| Interest Rate | 7.00% | 7.00% |
| Conversion Rights | 335,833 | 335,833 |
| Original Amount | $ 1,104,713 | $ 1,104,713 |
| Convertible Notes 2 [Member] | ||
| Interest Rate | 5.00% | 5.00% |
| Conversion Rights | 776,467 | 776,467 |
| Maturity Date, start | May 01, 2018 | May 01, 2018 |
| Maturity Date, end | Sep. 30, 2022 | Sep. 30, 2022 |
| Convertible Notes 3 [Member] | ||
| Interest Rate | 5.00% | 5.00% |
| Conversion Rights | 91,877 | 91,877 |
| Maturity Date | Jun. 30, 2022 | Jun. 30, 2022 |
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Long-term Debt, gross | $ 2,436,286 | $ 2,558,681 |
| Less unamortized debt discount | 16,303 | 0 |
| Long-term Debt | 2,419,983 | 2,558,681 |
| Bill Chaaban, President of Cen Biotech [Member] | ||
| Long-term Debt, gross | 1,388,122 | 1,388,122 |
| Director, Harold Aubrey de Lavenu [Member] | ||
| Long-term Debt, gross | 878,368 | 878,368 |
| Joseph Byrne [Member] | ||
| Long-term Debt, gross | 121,796 | 224,191 |
| Jeff Thomas [Member] | ||
| Long-term Debt, gross | 48,000 | 0 |
| Director, Alex Tarrabain [Member] | ||
| Long-term Debt, gross | 0 | 48,000 |
| Brother of Director Ameen Ferris [Member] | ||
| Long-term Debt, gross | $ 0 | $ 20,000 |
Note 8 - Convertible Notes Payable - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member] |
6 Months Ended | 12 Months Ended |
|---|---|---|
Jun. 30, 2021 |
Dec. 31, 2020 |
|
| Conversion Rights | 1,587,167 | |
| Bill Chaaban, President of Cen Biotech [Member] | ||
| Interest Rate | 12.00% | 12.00% |
| Conversion Rights | 867,576 | 867,576 |
| Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
| Director, Harold Aubrey de Lavenu [Member] | ||
| Interest Rate | 5.00% | 5.00% |
| Conversion Rights | 548,980 | 548,980 |
| Maturity Date | Mar. 31, 2019 | Mar. 31, 2019 |
| Joseph Byrne [Member] | ||
| Interest Rate | 12.00% | 12.00% |
| Conversion Rights | 76,123 | 76,123 |
| Maturity Date | Aug. 17, 2020 | Aug. 17, 2020 |
| Jeff Thomas [Member] | ||
| Interest Rate | 5.00% | 5.00% |
| Conversion Rights | 48,000 | 48,000 |
| Maturity Date | May 24, 2022 | May 24, 2022 |
| Director, Alex Tarrabain [Member] | ||
| Interest Rate | 5.00% | |
| Conversion Rights | 30,000 | |
| Brother of Director Ameen Ferris [Member] | ||
| Interest Rate | 5.00% | |
| Conversion Rights | 12,500 |
Note 9 - Income Taxes (Details Textual) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
|
| Operating Loss Carryforwards, Total | $ 28,900,000 | $ 28,900,000 | ||
| Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 4,100,000 | $ 600,000 | $ 4,200,000 | $ 700,000 |
Note 9 - Income Taxes - Reconciliation of Effective Tax Rate (Details) |
6 Months Ended | |
|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
|
| Income tax benefit at Canadian statutory rate | 26.50% | 26.50% |
| Valuation allowance | (26.50%) | (26.50%) |
| Effective income tax rate | 0.00% | 0.00% |
Note 9 - Income Taxes - Deferred Tax Assets (Details) - USD ($) |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Deferred tax asset - net operating losses | $ 7,600,000 | $ 3,400,000 |
| Deferred tax asset valuation allowance | (7,600,000) | (3,400,000) |
| Net deferred tax asset | $ 0 | $ 0 |
Note 10 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands |
Jun. 30, 2021 |
Dec. 31, 2020 |
|---|---|---|
| Common Stock, No Par Value (in dollars per share) | $ 0 | $ 0 |
| Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 2,791,344 |
Note 11 - Related Party Transactions - Future Minimum Operating Lease Payments (Details) |
Jun. 30, 2021
USD ($)
|
|---|---|
| 2022 | $ 48,392 |
| 2023 | 30,927 |
| 2024 | 32,820 |
| 2025 | 32,820 |
| 2026 | 32,820 |
| Thereafter | 41,025 |
| Total lease payments | 218,804 |
| Less imputed interest | 43,058 |
| Present value of lease liability | $ 175,746 |
Note 12 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Sep. 25, 2020 |
Aug. 27, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Non-vested, number of share (in shares) | 425,000 | 2,025,000 | 2,025,000 | |||||
| Non-vested, weighted average grant date fair value (in dollars per share) | $ 1.01 | $ 0.76 | $ 0.76 | |||||
| Non-vested, weighted average remaining contractual term (Year) | 1 year | 1 year 4 months 6 days | 1 year 6 months | 1 year 6 months 14 days | ||||
| Granted, number of share (in shares) | 162,500 | 162,500 | 12,059,291 | 225,000 | 12,059,291 | 225,000 | ||
| Granted, weighted average grant date fair value (in dollars per share) | $ 1.31 | $ 0.72 | ||||||
| Vested, number of share (in shares) | (12,134,291) | (900,000) | (12,209,291) | (1,237,500) | ||||
| Vested, weighted average grant date fair value (in dollars per share) | $ 1.30 | $ 0.68 | ||||||
| Forfeited, number of share (in shares) | 0 | 0 | ||||||
| Forfeited, weighted average grant date fair value (in dollars per share) | $ 0 | $ 0 | ||||||
| Non-vested, number of share (in shares) | 275,000 | 1,012,500 | 275,000 | 1,012,500 | 425,000 | 2,025,000 | ||
| Non-vested, weighted average grant date fair value (in dollars per share) | $ 1.01 | $ 0.84 | $ 1.01 | $ 0.84 | $ 1.01 | $ 0.76 | ||
Note 13 - Net Loss Per Share - Antidilutive Securities (Details) - shares |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
|
| Convertible Debt Securities [Member] | ||||
| Antidilutive Securities (in shares) | 2,657,697 | 5,482,166 | 2,631,484 | 5,376,040 |
-1Y$7CC;"^;1B.=]Q]U1M#:["#B45)5=6: 6&9[-@
M,?R\').]-_A=\(,]FP-E$FO]3(N[=!8,B!"7/'&$P'!XX2LN)0$AC7]:S* +
M28[G\Q/Z5Y\[YA(SRU=:_B%25\R"FP!2GK%:ND=]^,;;?*X(+]'2^E\X-+97
MXP"2VCI=ML[(H!2J&=EKJ\.9P\W@ X>H=8@\[R:09_F%.3:?> 0]:(1A.?
MJO=& P]%D;,L+^"6OU#6<0GW
MV-FA$%2$A,0G: